

BRUCE OVBIAGELE, MD MSc MAS

CONTACT DETAILS

- Address: 96 Jonathan Lucas Street,
CSB 301, MSC 606, Charleston, SC 29425
- Tel: 843-792-3224
- Fax: 843-792-6995
- Email: ovibes@musc.edu

EDUCATION

1. Degrees

- University of Lagos: Doctor of Medicine (MD), 12/1991
- University of California, Los Angeles: Master of Science (MSc) in Clinical Research, 09/2009
- University of California, San Diego: Master of Advanced Studies (MAS) in Leadership of Healthcare Organizations, 06/2012

2. Clinical Training

- Military Hospital, Lagos: Medical Housemanship, 1992 - 1993
- Presidential (State House) Hospital, Lagos, Nigeria: National Service Corps, 1993 -1994
- Citizens Hospital, Lagos: Medical Officership, 1994-1996
- Los Angeles County/King-Drew Medical Center: Dual Internships in Psychiatry and Internal Medicine, 1996-1998
- University of California, Irvine Medical Center and Long Beach Veterans Affairs Medical Center: Residency in General Neurology, 1998-2001
- University of California, Los Angeles, Medical Center: Fellowship in Vascular Neurology, 2001-2002

3. Research Training

- UCLA Clinical Research Course: Essentials of Clinical Investigation and Development of Research Proposals 07/02 – 08/02
- Harvard Post-Approval Summit: Phase IV studies, patient registries, and risk management programs 05/06
- AHA/CDC 32nd Ten-Day Seminar on the Epidemiology and Prevention of Cardiovascular Disease, Tahoe City, California 07/06 – 08/06
- UCLA Resource Center for Minority Aging Research (RCMAR) Scientific and Professional Writing Skills Workshop. Lynwood, California 02/07
- UCLA Resource Center for Minority Aging Research (RCMAR) Scientific and Professional Writing Skills Workshop II. Los Angeles, California 06/07

4. Pharmacological Training

- 5th International Experts Forum “Understanding molecular mechanisms of cyclooxygenase inhibition – a fundamental prerequisite for turning science

into practice” Sponsored by the Royal Society of Medicine and World Heart Federation. London, England 10/06

- National Institutes of Health (NIH) Principles of Clinical Pharmacology Course, Bethesda, Maryland 09/07 – 04/08

5. Ethics Training

- UCLA Ethics in Patient-Oriented Research Course. Los Angeles, California. 09/07 – 12/07

6. Management Training

- Completion of Tested Course Requirements for American College of Physician Executives (ACPE) Certification. 10/09 – 09/10

7. Leadership Training

- Selected Participant, *Harvard University Program for Chiefs of Clinical Services*, Boston, Massachusetts. January 13-25, 2013.
- Selected Participant, *Certifying Commission on Medical Management Program*. Tampa, Florida. February 20-24, 2011.
- Selected Participant, *2008 American Academy of Neurology Leadership Development Program*. Washington DC. March 1-3, 2008.

8. Advocacy Training

- Selected Participant, 2008 American Academy of Neurology “*Neurology on the Hill*”. Advocacy for Neurological Issues. March 4, 2008, Washington DC
- Selected Participant, 2009 American Academy of Neurology Advocacy Leadership Forum, San Diego, California

LICENSURE

- Medical License, South Carolina 2012 -
- Medical License, California 1998 –
- Drug Enforcement Agency Licensure, National 1998 –

BOARD CERTIFICATION

- Certifying Commission in Medical Management: Medical Management 2011
- American Board of Psychiatry and Neurology: General Neurology 2004
- American Board of Psychiatry and Neurology: Vascular Neurology 2005

HOSPITAL AFFILIATIONS:

- MUSC Medical Center, Charleston, SC (09/2012 -)
- Veterans Affairs Medical Center, Charleston, SC (02/2013 -)
- UCSD Medical Center, San Diego, CA (01/2011 – 08/2012)
- Veterans Affairs Medical Center, San Diego, CA (01/2011 – 08/2012)
- UCLA Medical Center, Los Angeles, CA (07/2001 – 12/2010)

- Olive View-UCLA Medical Center, Sylmar, CA (07/2001 – 12/2010)
- Santa Monica-UCLA Medical Center, Santa Monica, CA (07/2008 – 12/2010)

PROFESSIONAL EXPERIENCE:

1. Academic Faculty Positions

- Admiral Paul E. Pihl Endowed Professor of Neurosciences, Medical University of South Carolina, 09/2012 –
- Professor of Neurology, Medical University of South Carolina, 09/2012 –
- Professor of Public Health Sciences, Medical University of South Carolina, 05/2014 –
- Full Member, College of Graduate Studies, Medical University of South Carolina, 11/2014 –
- Professor of Neurosciences, University of California, San Diego, CA 01/2011 – 08/2012
- Associate Professor of Neurology, University of California, Los Angeles, CA 07/2007 – 12/2010
- Assistant Professor of Neurology, University of California, Los Angeles, CA 07/2002 – 06/2007
- Clinical Instructor, Department of Neurology, UCLA, Los Angeles, CA 07/2001 – 06/2002

2. Administrative Positions

- Chairman/Head of Neurology, Medical University of South Carolina, 09/2012 –
- Acting Chairman of Neurosurgery, Medical University of South Carolina, 01/2014 – 12/2014
- Medical Director, Neurosciences Service Line, Medical University Hospital Authority, Medical University of South Carolina, 09/2012 -
- Director, San Diego Veteran Affairs Medical Center Stroke Program, La Jolla, CA 01/2011 – 08/2012
- Chief, San Diego Veteran Affairs Medical Center Comprehensive Stroke Clinic, La Jolla, CA 07/2011 – 08/2012
- Director, Olive View-UCLA Medical Center Stroke Program, Sylmar, CA 07/2002 – 12/2010
- Chief, Olive View-UCLA Medical Center Comprehensive Stroke Clinic, Sylmar, CA 07/2002 – 12/2010
- Supervisor, Vascular Neurology Residency, Olive View-UCLA Medical Center, Sylmar, CA 07/2004 – 12/2010
- Director, UCLA Stroke PROTECT Program, UCLA Medical Center, Los Angeles, CA 04/2002 – 12/2010
- Chief Resident, Department of Neurology UC Irvine, Orange, CA 04-06/2001
- Assistant Chief Resident, Department of Psychiatry, UCLA-Drew, Los Angeles, CA 07/1997 – 06/1998

3. Clinical Staff/Attending Neurologist Positions

- Staff Physician, Charleston Veterans Affairs Medical Center, Charleston, SC 02/2013 -
- Attending Neurologist, Neurology Service, Medical University of South Carolina Medical Center, 09/2012 –
- Attending Neurologist, Neurology Service, UCSD Medical Centers (Hillcrest and Thornton), 01/2011-08/2012
- Staff Physician, San Diego Veterans Affairs Medical Center, San Diego, CA 01/2011 – 08/2012
- Staff Physician, Alvarado Hospital, San Diego, CA 01/2011 – 08/2012
- Staff Physician, Scripps-Mercy Medical Center, San Diego, CA 04/2011 – 08/2012
- Attending Neurologist, Stroke Service, UCLA Medical Center, Los Angeles, CA 07/2001-12/2010
- Attending Neurologist, Neurology Service, Olive View-UCLA Medical Center, Sylmar, CA 07/2001- 12/2010
- Staff Physician, Santa Monica-UCLA Medical Center, Los Angeles, CA 07/2008 –12/2010

4. Clinical Service Responsibilities

- Attending, Charleston Veterans Affairs Medical Center Neurology Inpatient Services, 6 weeks per year, 02/2013 -
- Attending, MUSC Inpatient Stroke Service, Weekend Coverage (4 X per year),
- Supervising Attending of vascular neurology fellow in MUSC continuity stroke clinic, 02/2013 -
- Supervising Attending of vascular neurology fellow in Charleston Veterans Affairs Medical Center stroke clinic, 02/2013 -
- Supervising Attending of vascular neurology fellows in San Diego Veterans Affairs stroke clinic, 02/2011 – 08/2012
- Supervising Attending of general neurology residents in San Diego Veterans Affairs continuity general neurology clinic, 02/2011 – 08/2012
- UCSD-Hillcrest and UCSD-Thornton/San Diego Veterans Affairs Neurology Inpatient Services, one month per year, 01/2011
- UCLA Neurology Service, Attending, one to three months per year, 07/2002-12/2010
- UCLA Neurology Outpatient clinic, one half day per week
- Supervising Attending of vascular neurology residents in Olive View-UCLA continuity stroke clinic
- Supervising Attending of general neurology residents in Olive View-UCLA continuity general neurology clinic, 07/2002-12/2010
- UCLA Stroke service, Attending back-up call, 6-7 days/month, 07/2002-12/2010

PROFESSIONAL ACTIVITIES

1. Program and Advisory Committees

- Chair, International Stroke Conference Program Committee, 2016-
- Member, National Advisory Neurological Disorders and Stroke (NANDSC) 2015-
- Member, FDA Peripheral and Central Nervous System Drugs Advisory Committee, 2014-
- Member, Data and Safety Monitoring Board of the NIH-PCORI Hypertension Disparities Reduction Program Partnership (HDR-PP), 2016-
- Vice-Chair of the Cardiovascular Disease in Women & Special Populations Committee, American Heart Association, 2014-
- Chair, American Academy of Neurology, Global Health and Infectious Disease Topic Work Group, 2013-
- Chair, Outcomes Research Working Group, World Federation of Neurology (WFN), 2012 –
- Chair, Program Advisory Committee (PAC), Kaiser-UCSF NINDS Stroke Prevention/Intervention Research Program (SPIRP), 2013 –
- Co-Chair, Recurrent Stroke Prevention Group, NINDS-IDEAS Workshop: Framework for Interventions to Prevent Recurrent Stroke in Disparities Populations, 2013 – 2014
- Member, American Academy of Neurology Education Committee, 2013-
- Member, Virtual International Stroke Trials Archive (VISTA) Prevention Steering Committee, 2012 -
- Member, Science Advisory & Coordinating Committee, American Heart Association, 2012 – 2014
- Member, Research Committee, American Heart Association, 2012 – 2014
- Chair, Minority Affairs Committee, American Heart Association Stroke Council, 2009 – 2012
- Member, NIH-NINDS Committee on Cognitive norms data for the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study, 2010
- Member, NIH-NINDS Advisory Panel: Health Disparities Development, 2010
- Member, American Academy of Neurology/American Brain Foundation Minority Scholars Subcommittee, 2010 -
- Member, AHA-ASA Stroke Council Leadership Committee, 2009 – 2012
- Member, National Quality Forum Steering Committee on National Voluntary Consensus Standards for Prevention and Management of Stroke Across the Continuum of Care, 2008 – 2010
- Member, Adherence Evaluation After Ischemic Stroke Longitudinal Registry (AVAIL) publications committee, 2009 – 2011
- Member, Cardiovascular Health Study Neurology Working Group, 2009 –

- Member, American Academy of Neurology Clinical Research Subcommittee 2007 – 2011
- Member, Annual Stroke Track Committee, AHA Quality of Care and Outcomes Research Conference
- Member, Western States Affiliates Board of Directors of the American Heart Association 2007 - 2010
- Member, American Heart Association Western Affiliates Budget and Finance Committee 2007 – 2010
- Member, American Heart Association Stroke Council Professional Education Committee 2006 –
- Member, American Heart Association Women and Minorities Leadership Committee 2006 - 2007
- Member, Los Angeles County Affiliate Board of Directors of the American Heart Association 2005 - 2007
- Member, American Heart Association Western Affiliates Stroke Task Force 2005 - 2007
- Member, Stroke and Vascular Neurology Section of the American Academy of Neurology 2005
- Co-Chair, American Heart Association Operation Stroke Medical/Education Committee - Los Angeles 2003 – 2004
- Co-Chair, Stroke Education Program (SEP) Executive Committee, 2003 – 2005
- Co-Chair, NIH Stroke Progress Review: Prevention of First and Recurrent Stroke Working Group, 2006 –
- Member, Jackson Heart Study Emerging Science Group 2006 - 2007
- Member, California Department of Public Health Stroke Systems Work Group, 2007 – 2010
- Member, American Heart Association Stroke Advisory Committee 2005 – 2008

2. Institutional Committees

- Member, Medical University of South Carolina College of Medicine Faculty Compensation Committee, 2014-
- Member, Medical University of South Carolina College of Medicine Physician Executive Committee, 2012-
- Member, Medical University of South Carolina College of Medicine Dean's Advisory Committee, 2012-
- Member, Medical University of South Carolina College of Medicine Clinical Chairs Committee, 2012-
- Member, Medical University of South Carolina College of Medicine Faculty Compensation Committee
- Member, Olive View/ UCLA Medical Center Internal Review Board (IRB) 2005 - 2010
- Member, Los Angeles County Acute Ischemic Stroke Clinical Resource Management (CRM) Content Team 2005 –

- Member, Olive View/ UCLA Medical Center Pharmacy and Therapeutics Committee 2006 -
- Member, Olive View/ UCLA Medical Center Performance - Improvement Committee 2004 – 2005
- Member, UCLA School of Medicine Faculty Partners for Diversity Committee, 2009 -

3. Review Panels

- Expert Referee, National Institute For Health Research Central Commissioning Facility For the United Kingdom Dept of Health: Health Applied Research Programme Grant Applications, 2006
- American Heart Association Peer Review Grant Award Committee, , Western States and Texas Affiliates, 2006 - 2008
- American Academy of Neurology Clinical Research Training Fellowship Award Committee, 2007 - 2010
- NIH-NINDS Clinical Trial Planning Grant (R34) Review {Special Emphasis Panel: ZNS1 SRB-G} Committee, 2007
- Sub-Chair, NIH-NINDS SPIRP Special Emphasis Panel ZNS1 SRB N(02). Bethesda, MD July 26, 2012 – July 27, 2012.

4. Conference Session Chair

- Co-Chair, Etiology of Stroke and Risk Factors Session, European Stroke Conference, Nice, France. May 8, 2014.
- Co-Chair, Prevention Oral Abstract Presentations Session, 2006 International Stroke Conference, Thursday, Feb. 16 7:30-9:00 a.m. Kissimmee, Florida.
- Co-Chair, International Society for Hypertension in Blacks (ISHIB) 2006 Symposium: Peripheral Arterial Disease Session, Sunday June 25 2006, 6:30-8:15 a.m., Atlanta, Georgia
- Co-Chair, 60th American Academy of Neurology Annual Meeting. Cerebrovascular Diseases: Prevention Abstract Platform Presentations April 16th 2008. 2:00-3:30 pm. Chicago, Illinois.
- Co-Chair, AHA-ASA International Stroke Conference Symposium. “Secondary Prevention Adherence: Identifying Barriers and Novel Strategies for Improvement”. February 25th 2010. San Antonio, Texas.
- Co-Chair, 61st Annual Meeting of the American Academy of Neurology. Session S49: Stroke Prevention and Outcomes on Thursday, April 30, 2009. Seattle, Washington.
- Co-Chair, 62nd Annual Meeting of the American Academy of Neurology. Session S42: Cerebrovascular Disease: Stroke Prevention. Thursday, April 15, 2010. Toronto, Canada.
- Chair, Community/Risk Factors Category, AHA-ASA International Stroke Conference, 2009 –
- Member, AHA-ASA International Stroke Conference Program Committee, 2009 –

- Member, Scientific Committee, European Stroke Conference, 2010 –
- Chair, Pre-Conference Symposium Planning Committee for the International Stroke Conference, 2010 – 2011
- Co-Chair, 64th Annual Meeting of the American Academy of Neurology. Session S19: Ischemic Cerebrovascular Disease and Subarachnoid Hemorrhage. Tuesday, April 24, 2012. New Orleans, Louisiana.
- Co-Chair, European Stroke Conference Meeting Session “Etiology of stroke and risk factors”, May 8, 2014. Nice, France.

5. National Spokesperson Panels

- Member, American Academy of Neurology Media Expert Panel, 2011 –
- Member, American Heart/Stroke Association National Spokesperson Panel, 2005 –
- National Medical Spokesperson, American Heart Association National African American Community Awareness Campaign “The Power to End Stroke” 2005 – 2006
- National Medical Spokesperson, National Stroke Association “Steps Against Recurrent Stroke” (STARS) Campaign, 2008 – 2009

6. Professional Society Memberships

- American Academy of Neurology 01/99 –
- American Heart Association Stroke Council 02/02 –
- American Society of Neuroimaging 01/03 –
- Western States Stroke Consortium 01/03 –
- American Heart Association Council on Epidemiology and Prevention 08/06 –
- American College of Physician Executives, 07/09 -
- American Neurological Association, 05/11 –
- European Stroke Organization, 06/14 -

7. National Expert Guideline Writing Committees

- Vice-Chair, , American Stroke Association Post-Stroke Depression Scientific Statement Writing Committee, 2014 - 2016
- Vice-Chair, American Stroke Association Recurrent Stroke Prevention Clinical Practice Guideline Writing Committee, 2012 – 2014
- Chair, American Stroke Association Forecasting the future of stroke in the United States Policy Statement Writing Committee, 2011 – 2013
- Member, American Stroke Association Recurrent Stroke Prevention Clinical Practice Guideline Writing Committee, 2008 – 2011
- Member, American Academy of Neurology Carotid Angioplasty/Stenting Clinical Practice Guideline Writing Committee, 2008 – 2010
- Member, American Heart Association Practice Guideline Writing Group for “Race-Ethnic Disparities in Stroke Care.” 2008 – 2011

8. National Board Examiner Duties

- Oral Board Examiner, American Board of Psychiatry and Neurology. 2005
- Member, Vascular Neurology Examination-Writing Committee of the American Board of Psychiatry and Neurology (ABPN). 2008 – 2010

9. Educational Leadership Positions

- American Academy of Neurology: Course Director, “Therapy Program: Stroke” 6TP.003 for the American Academy of Neurology Annual Meeting, 2009 –
- American Academy of Neurology: Faculty Chair/Guest Editor, AAN Continuum Issue entitled “Secondary Stroke Prevention”(published in 12/2011)
- American Academy of Neurology: Director, “Stroke Update” Program for the American Academy of Neurology Fall Conference, October 26th 2012. Las Vegas, Nevada.

10. Industry Consultantships

- Scientific Consultant, BMS/Sanofi-Aventis Neurology Working Group 2005
- Scientific Consultant, Bayer North American Experts Advisory Board 2006
- Consultant, AHA/Pfizer Treatment Adherence Workshop 2006
- Scientific Consultant, Boehringer-Ingelheim, 2008
- Scientific Consultant, Avanir Pharmaceuticals, 2010
- Scientific Consultant, Avanir Pharmaceuticals, 2011

11. Faculty Promotion Review for External Institutions

- Columbia University
- University of California, Los Angeles
- University of Michigan
- University of California, San Diego
- University of Pittsburgh
- University of California, Irvine
- University of Southern California

AWARDS

- Charles Drew University Department of Psychiatry: Intern of the year, Los Angeles, 1997
- American Stroke Association National Volunteer Service Award: for “commitment and dedication to the Power to End Stroke” campaign, May 18th 2006, Santa Monica, CA
- American Heart Association Western Affiliates Certificate of Appreciation for “conducting LAUSD high school student Hypertension Study”. May 1st, 2008, Los Angeles, CA
- American Academy of Neurology: Michael S. Pessin Stroke Research Leadership Award, Chicago Illinois, April 2008

- American Heart Association: Award for Distinguished Service on the Western Affiliates Board of Directors, Los Angeles, CA, 2010

HONORS (Academic)

- University of California, Los Angeles: Accelerated Promotion to Associate Clinical Professor, 2007.
- University of California, Los Angeles: Professorial Series Change to Associate Professor Regular Series (tenured rank), 2008.
- University of California, Los Angeles: Member, Academic Senate, 07/08-12/10
- University of California, San Diego: Member, Academic Senate, 01/11 – 08/12

HONORS (Professional)

- Elected Fellow, Royal College of Physicians (FRCP), London, U.K., 2015
- Elected Fellow, American College of Physician Executives (FACPE), 2015
- Member, Aspen Global Leadership Network – Aspen Institute, 2014
- Elected Fellow, Liberty Leadership Program, South Carolina, 2014
- Elected Fellow, European Stroke Organization (FESO) 2014
- Elected Fellow, American Academy of Neurology (FAAN), 2011
- Elected Fellow, American Neurological Association (FANA), 2011
- Elected Fellow, American Heart Association (FAHA) Stroke Council, 2003

HONORS (Visiting Professorships and Endowed Lectures)

- University of Southern California Roxana Todd Hodges Lecture in Stroke Prevention and Education. *“Chronic Kidney Disease and the Risk of Stroke: An Epiphenomenon or A Real Culprit?”* Los Angeles, CA. July 31, 2012.
- American Academy of Neurology Foundation 2011 Visiting Professorship: Morehouse School of Medicine, Atlanta, GA, November 2011
- University of Michigan Visiting Professorship: Department of Neurology, May 2011

EDITORIAL RESPONSIBILITIES

1. Conference Abstract Reviewer

- American Stroke Association International Stroke Conference 2006 –
- American Academy of Neurology Annual Meeting 2009, 2011
- European Stroke Conference Annual Meeting 2010 –
- American Neurological Association Annual Meeting 2012 -

2. Journal Ad hoc Reviewer

- Annals of Internal Medicine, 2010
- Annals of Neurology 2002, 2007, 2008 -

- Stroke 2003 -
- Neurology 2004 –
- Nature Reviews Neuroscience 2005
- Neurotherapeutics 2005
- Lancet Neurology 2005, 2010
- Lancet 2005, 2006, 2011
- Journal of Hospital Medicine 2006
- Hospital Physician 2006
- European Journal of Neurology 2006
- Acta Neurologica Scandinavica 2006
- Journal of Neurology, Neurosurgery, and Psychiatry 2007
- Journal of Neurology 2007
- Cerebrovascular Diseases 2007, 2010
- Brain 2007
- PLOS Medicine 2008
- Arteriosclerosis, Thrombosis, and Vascular Biology 2008
- The Neurologist 2008
- Archives of Neurology 2008 -
- Neuroepidemiology 2008
- Circulation 2009 –
- International Journal of Stroke 2009

3. Editorial Board/Consultant

- Lancet 2005 – 2012
- Journal of Stroke and Cerebrovascular Diseases 2008 –
- Stroke Research and Treatment 2009 –

4. Editorships

- Founding Editor-in-Chief, eNeurologicalSci (eNS), 2014 –
- Lead Editor, “Post-Stroke Outcomes”, Stroke Research and Treatment, 10/2014
- Associate Editor, Journal of Neurological Sciences, 2013 -
- Consulting Editor, Stroke 2011 -
- Assistant Editor, Stroke 2010 –
- Associate Editor, Journal Watch Neurology 2010 - 2012
- Associate Editor, Biomed Central (BMC) Public Health 2009 – 2012

MENTORING

1. Vascular Neurology Fellows



(b) (6)



2. Neurology Resident Research

(b) (6)



3. Visiting Scholar Research

(b) (6)



4. Coordinator/Student Research

(b) (6)



5. Thesis Committee

6. Awards for Mentees

(b) (6)

ACTIVE GRANTS

1. Principal Investigator (BO):

- Sponsor: NIH-NINDS (U01)
- Project: Tailored Hospital-based Risk Reduction to Impede Vascular Events after Stroke (THRIVES)
- U01NS079179
- Coordinating center: Medical University of South Carolina
- Duration: May 2012 – April 2017
- Amount (direct): \$2.1M

2. Principal Investigator (BO):

- Sponsor: NHGRI and NIH-NINDS (U54)
- Project: Stroke Investigative Research and Education Network (SIREN)
- 1U54HG007479
- Coordinating center: University of Ibadan, Nigeria
- Duration: September 2013 – August 2017
- Amount (direct): \$3.6M

3. Principal Investigator (BO):

- Sponsor: NIH-NINDS (R21)
- Project: Phone-based Intervention Under Nurse Guidance after Stroke (PINGS)
- R21NS094033
- Coordinating center: Medical University of South Carolina
- Duration: August 2015 – July 2017
- Amount (direct): \$260,430

RECENT GRANTS

1. Co-investigator (Alexander Dromerick, PI):

- Sponsor: NIH-NINDS (1U54NS057405-01A1)
- Project: Preventing Recurrence of Thromboembolic Events through Coordinated Treatment in the District of Columbia (PROTECT DC)
- Coordinating center: Georgetown University
- Duration: Sep 2007 – August 2013

2. Co-investigator (Arleen Brown, PI)
 - Sponsor: American Heart Association
 - Project: Are neighborhood characteristics associated with stroke incidence and outcomes?
 - Coordinating center: University of California, Los Angeles
 - Duration: 2008 – 2013
3. Co-investigator (George Howard, PI)
 - Sponsor: NIH-NINDS
 - Project: Reasons for Geographic And Racial Differences in Stroke (REGARDS)
 - Coordinating center: University of Alabama
 - Duration: 2008 – 2012
4. Co-investigator (Brett Meyer, PI)
 - Sponsor: NIH-NINDS (P50)
 - Project: Specialized Program of Translational Research in Acute Stroke, Cycle 2
 - Coordinating center: University of California, San Diego
 - Duration: 2011 - 2012

PREVIOUS RESEARCH

1. Principal Investigator (BO):
 - Sponsor: RCMAR/NIH/NIA Grant P30-AG021684
 - Project: Adaptation and Development in High risk Hispanic Elderly patients of a Report card intervention to prevent vascular Events (ADHERE) project
 - Duration: May 2007 – April 2010
2. Principal Investigator (BO):
 - Sponsor: Iris Cantor-UCLA National Center of Excellence in Women's Health Research
 - Project: Intensive Lipid Lowering Using MR Imaging of the Neck to Assess Treatment Efficacy (ILLUMINATE) in Women trial
 - Duration: July 2006 – January 2010
3. Co-investigator (Cheryl Bushnell, PI)
 - Project: Adherence Evaluation After Ischemic Stroke Longitudinal Registry (AVAIL)
 - Sponsor: American Heart Association
 - Coordinating center: Duke University
 - Duration: 2007 – January 2010

4. Co-investigator (Walter Kernan, PI)
 - Insulin Resistance In Stroke (IRIS) Study.
 - Overall Study Principal Investigator: Walter Kernan
 - Sponsor: NIH-NINDS
 - Coordinating Center: Yale University
 - Duration: September 2004 – December 2010
5. Principal Investigator (BO - UCLA)
 - Title: Prevention Regimen for Effectively Avoiding Second Strokes
 - Sponsor: Boehringer-Ingelheim
 - Duration: 7/04 – 06/08
6. Principal Investigator (BO)
 - Title: Systematic Use of Stroke Averting Interventions (SUSTAIN)
 - Sponsor: American Heart Association/Pharmaceutical Roundtable-Spina
 - Duration: 06/08 – 10/08
7. Warfarin vs Aspirin for Stroke in Intracranial Disease (WASID)
NIH-NINDS
Co-Investigator (UCLA), 2001-2004
8. Pilot Trials of Paramedic Initiation of Neuroprotective (Magnesium) Stroke Therapy in the Field
NIH-NINDS K24 NS 02092-01
Co-Investigator, 7/1/01-6/30/04
9. Bugher Award for Stroke Research
American Heart Association
Co- Investigator, 7/01-6/04
10. MRI Endpoint Trial of Magnesium for Acute Ischemic Stroke
NIH.NINDS K23 Award Mentored Clinical Scientist Development Award
Co-Investigator, 7/01-6/04
11. Intravenous Magnesium Efficacy in Acute Stroke (IMAGES) Trial
Medical Research Council, Great Britain
Co-Investigator, 7/01-12/03
12. Asymptomatic Carotid MicroEmboli Study (ACES)
Medical Research Council, Great Britain
Co-Investigator, 7/01-12/04
13. Siblings With Ischemic Stroke Study (SWISS)
NIH-NINDS RO1 Award
Co-Investigator, 7/01-6/04

(b) (4)

15. Carotid Occlusion Stroke Study (COSS)

NIH-NINDS RO1 Award

Co-Investigator, 3/02-6/05

16. Interventional Management of Stroke (IMS) Study

NIH-NINDS RO1 Award

Co-Investigator, 6/03-12/10

17. The Combined Approach to Lysis Utilizing Eptifibatide and rt-PA in Acute Ischemic Stroke (CLEAR) Trial

NIH-NINDS P50 Award

Co-Investigator, 8/03-06/07

(b) (4)

21. Specialized Program of Translational Research in Acute Stroke

NIH-NINDS P50 NS044378

Co-Investigator, 1/1/04-12/31/08

22. Field Administration of Stroke Therapy – Magnesium (FAST-MAG) Phase 3 Trial

NIH-NINDS U01 NS 44364

Co-Investigator, 10/1/03-12/31/2009

23. California Acute Stroke Pilot Registry (CASPR)

Centers for Disease Control

Co-Investigator, 1/1/03-12/31/04

(b) (4)

26. A Randomized Multicenter Clinical Trial of Unruptured Brain AVMs (ARUBA)
NIH-NINDS
Co-Investigator, 1/1/2006-12/31/2010
27. Interventional Management of Stroke Trial III
NIH-NINDS
Co-Investigator, 1/1/2006-12/31/2009
28. The Combined Approach to Lysis Utilizing Eptifibatide and rt-PA in Acute Ischemic Stroke (CLEAR) Trial
NIH-NINDS
Co-Investigator, 1/1/2004-12/31/2008
29. Specialized Program of Translational Research in Acute Stroke, Cycle 2
NIH-NINDS P50 NS044378
Co-Investigator (UCLA), 5/1/08-12/2010

LECTURES AND PRESENTATIONS

First Author Peer Reviewed Abstract Platform Presentations at International Meetings

1. 55th American Academy of Neurology Annual Meeting: "In-Hospital Initiation of Secondary Prevention for Symptomatic Cerebrovascular Atherosclerosis Yields High Rates of Compliance at Follow-Up" #S31.001 - Cerebrovascular Disease: Prevention Session, San Francisco, CA. April 28th 2004.
2. 57th American Academy of Neurology Annual Meeting: "The Metabolic Syndrome is Highly Prevalent and is Associated with Increased Risk for Recurrent Vascular Events among Individuals with Symptomatic Intracranial Disease" #S31.005 – Stroke Epidemiology 1 Session, Miami Beach, Florida, CA. April 12th 2005.
3. American Stroke Association International Stroke Conference: "Elevated White Blood Cell Count and Increased Risk for Stroke and Vascular Death in Patients with Symptomatic Intracranial Disease". Session V: Concurrent C Outcomes Oral Abstracts Presentations I: Clinical Epidemiology. Kissimmee, Florida. February 16th 2006.

4. 58th American Academy of Neurology Annual Meeting: “Elevated Calcium Level Is Associated with Lesser Stroke Severity and Better Discharge Functional Outcome in Ischemic Stroke Patients” # S26.001, San Diego, CA. April 5th 2006.
5. 21st European Stroke Conference: “Chronic Kidney Disease and Recurrent Vascular Risk after a Recent Ischemic Stroke” AID 1336. Session: Etiology of stroke and risk factors. May 23, 2012. Lisbon, Portugal

Invited Platform Presentations at National/International Meetings

1. National Stroke Association (NSA) Stroke Meeting: The Stroke PROTECT Program and Secondary Stroke Prevention Lifestyle Modification” December 3rd 2003. Orlando, Florida.
2. National Stroke Association (NSA) Stroke Team Meeting. “The Metabolic Syndrome: Why the Fuss, and What Has it Got to do with Stroke” September 10th, 2005, Scottsdale, Arizona.
3. National Stroke Association (NSA) Stroke Team Meeting. “Modifying Risk Factors of Stroke ... Strategies to Change Behaviors for the Out Patient Setting” September 10th, 2005, Scottsdale, Arizona.
4. International Society for Hypertension in Blacks (ISHIB) Symposium, ‘Peripheral arterial disease and Stroke’, June 25, 2006, Atlanta, Georgia.
5. International Society for Hypertension in Blacks (ISHIB) Symposium. “Prevention and Management of Stroke in High-Risk Populations” June 25th, 2006, Atlanta, Georgia.
6. National Stroke Association (NSA)/ Western States Stroke Consortium Meeting. “Ethnic Differences in Stroke: Latino, Native American, African Americans and Asian Americans”. September 10th, 2006. Las Vegas, Nevada.
7. 59th American Academy of Neurology Annual Meeting. Contemporary Clinical Issues and Case Studies Plenary Session: Discussion of the “Secondary Analysis of Hemorrhagic Stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study”. May 2nd 2007. Boston, Massachusetts.
8. International Conference on the PROTÉGÉ ACV Stroke Program. “Multidisciplinary Stroke Prevention: the UCLA PROTECT Experience” September 14th 2007. Buenos Aires, Argentina.
9. 60th American Academy of Neurology Annual Meeting Pessin Award Lecture. “Lessons from the PROTECT Program: Translating Clinical

- Research Evidence into Routine Clinical Practice” April 15th 2008. Chicago, Illinois.
10. 60th American Academy of Neurology Annual Meeting. Scientific Highlights “April 17th 2008. Chicago, Illinois.
 11. American Heart Association Scientific Sessions. “The High-Risk Stroke Patient: Intracranial Atherosclerosis. What is Maximal Medical Management?” November 16, 2009. Orlando, Florida.
 12. 19th European Stroke Conference. “Secondary stroke prevention principles: how to apply in the elderly?” May 25, 2010. Barcelona, Spain.
 13. 64th American Academy of Neurology Annual Meeting. Secondary stroke prevention. Session: 3PC.003: *Continuum*® Test Your Knowledge: A Multiple-Choice Question Review. April 23, 2012. New Orleans, Louisiana.
 14. 21st European Stroke Conference. “*Prevention in the very elderly patient*” May 25, 2012. Lisbon, Portugal.
 15. 22nd European Stroke Conference, “*Association of Biomarkers of Renal Disease with Subclinical Vascular Brain Injury*”. May 30, 2013. London, England.
 16. XXI World Congress of Neurology. “*The art and science of writing about clinical outcomes in neurology*”. September 23, 2013. Vienna, Austria.
 17. XXI World Congress of Neurology. “*Interpreting and publishing trial results*”. September 24, 2013. Vienna, Austria.
 18. American Society of Nephrology “Kidney Week”. “*Effect of CKD on Stroke Risk and Outcomes*”. November 9, 2013. Atlanta, GA.
 19. NIH IDEAS Stroke Disparities workshop. “*Secondary Prevention: Summary of Knowledge Base*”. Washington, DC on November 20, 2013.
 20. NIH IDEAS Stroke Disparities workshop “*Secondary Prevention: Promising strategies for interventions*”. Washington, DC on November 21, 2013.

21. GACD/NIH Meeting: "Results of a Qualitative Study for T3 Stroke Translation in Nigeria". Bethesda, MD. April 13, 2014
22. 6th Annual New York State Stroke Conference (sponsored by the New York State Department of Health): Keynote Lecture: *"The Aftermath of Acute Stroke: Not all Prevention Programs are Created Equal"*. New York, NY. May 29, 2014
23. University of Ibadan, Nigeria Plenary Lecture: *"Renocerebrovascular Disease: A New Frontier in the Prevention and Treatment of Stroke?"*, Ibadan, Nigeria on August 12, 2014.
24. Global Alliance for Chronic Diseases-Hypertension Meeting: *"Update on the Progress of the THRIVES Study"*. Xi'an, China. November 13, 2014
25. 67th American Academy of Neurology Annual Meeting: *"Obesity and Stroke"*. Washington, DC. April 23, 2015.
26. 1st European Stroke Organization Conference: *"Transient Ischemic Attack: Organization and Work-up"*. Glasgow, Scotland. April 19, 2015
27. Chang Gung University College of Medicine Neurology Grand Rounds:, *"Nephron and Neuron: Drawing the link between kidney damage and vascular brain injury"*. Chiayi, Taiwan. May 6, 2015.
28. First International Taiwanese Congress of Neurology: *"Stroke Risk and Outcomes: The Emerging Role of Chronic Kidney Disease"*. Taipei, Taiwan. May 7, 2015.
29. American Society of Hypertension Annual Meeting: *"Hypertension and the Brain: Acute Management of Blood Pressure"*. New York, NY. May 16, 2015.
30. American Association of Physicians of Indian Origin Convention: *"Secondary Prevention of Stroke"*. Orlando, FL. June 19, 2015.
31. Xuan Wu Hospital/Capital University: *"Frequently Overlooked: The Kidney's Relationship to Vascular Brain Injury"*. Beijing, China. June 26, 2015.

32. Tiantan International Stroke Conference: *"Role of optimal combination therapy in stroke prevention"*. Beijing, China. June 27, 2015.

Invited Presentations at University Grand Rounds/Symposia

1. University of Washington/Swedish Medical Center Stroke Symposium: "Assuring Compliance with Secondary Prevention". Seattle, Washington. May 6th 2005
2. University of Utah Stroke Symposium. "Strategies for Modifying Stroke Risk", Salt Lake City, Utah. March 25th 2006.
3. St Louis University Grand Rounds: "Assuring Stroke Prevention in the Post-discharge" Setting March 2009, St Louis, Missouri
4. University of Florida Noon Lecture: "Intensive Medical Treatment for Symptomatic Intracranial Stenosis" January 25th 2010, Gainesville, Florida
5. University of Florida Neurology Grand Rounds: "Implementation of Systematic Evidence-based Stroke Prevention". January 26th 2010, Gainesville, Florida.
6. University of California, San Diego Neurology Grand Rounds: "Reno-cerebrovascular Disease: Protect the Kidney, Protect the Brain?". April 30, 2010, San Diego, California.
7. 5th Annual Yale University/Lawrence Brass Stroke Symposium: "Antiplatelet and Anticoagulation Treatment after Stroke". New Haven, CT. October 6, 2011.
8. University of California, Irvine Stroke Symposium: "Chronic Kidney Disease: Emerging Risk Marker or Risk Factor for Stroke?" Newport Beach, California. October 29, 2011
9. Medical University of South Carolina Special Seminar: "Vascular Risk Reduction after Stroke: something old, new, borrowed, and not true?" Charleston, South Carolina. March 26, 2012.
10. Albert Einstein College of Medicine Neurology Grand Rounds: "Chronic Kidney Disease - Emerging Risk Marker or Treatable Risk Factor for Stroke?" Bronx, New York. June 14, 2012.
11. University of Texas Southwestern Neurology Conference: "Reno-Cerebrovascular Disease: Associative or Causal Connection?" Dallas, Texas. June 26, 2012.

12. South Carolina Neurological Association annual meeting *"Prevention of Secondary Stroke: An Update"*. October, 2013. Charleston, SC.
13. Wake-Med Health & Hospitals 8th Annual Stroke Program. *"Secondary Stroke Prevention: What have we learned?"* October, 2013. Raleigh, NC.
14. University of South Carolina Department of Neurology Grand Rounds. *"Effect of CKD on Stroke Risk and Outcomes"*. Columbia, SC. April 16, 2015
15. University of Washington Resident Lecture Series: *"Emerging Stroke Risk Factors I: Obesity and Risk of Stroke – Fat Chance?"* Seattle, WA. June 4, 2015.
16. University of Washington Neurology Grand Rounds: *"Emerging Stroke Risk Factors II: Chronic Kidney Disease – Risk Marker or Modifiable Risk Factor?"* Seattle, WA. June 4, 2015.

Invited Presentations at Local Meetings/ Courses/Grand Rounds

1. 18th Annual UCLA Intensive Course in Geriatric Medicine and Board Review: *"Stroke Disease"*. September 2001; Radisson Hotel, Marina Del Rey, CA.
2. 19th Annual UCLA Intensive Course in Geriatric Medicine and Board Review: *"Stroke Prevention"*. September 2002; Radisson Hotel, Marina Del Rey, CA
3. UCLA 'Brain Attack' Stroke Prevention Series: *"Antiplatelet therapies in secondary stroke prevention"*. October, 2001; Beverly Hilton Hotel, Beverly Hills, CA.
4. UCLA Transcranial and Cerebral Blood Flow Monitoring Fellowship Course. *"Monitoring Stroke Risk in Sickle Cell Anemia"* March 2003; UCLA Medical Center, Los Angeles, CA.
5. UCLA "Brain Attack" Stroke Prevention Series: *"Antiplatelet therapies in secondary stroke prevention"*. May, 2003; Beverly Hilton Hotel, Beverly Hills, CA.
6. UCLA Vascular Surgery Conference: *"Thrombolysis in Acute Ischemic Stroke"* 20003, October 3rd, 2003; Beverly Hilton Hotel, Beverly Hills, CA.
7. UCLA Transcranial and Cerebral Blood Flow Monitoring Fellowship Course. *"Monitoring Stroke Risk in Sickle Cell Anemia"* March 2004; UCLA Medical Center, Los Angeles, CA.
8. UCLA Brain Attack Symposium: *"Secondary Stroke Prevention in 2004"*; Beverly Hills Hotel, Beverly Hills, CA. May 15th 2004.
9. UCLA Family Practice Refresher Course. *"Advances in Stroke Prevention"*; Beverly Hilton Hotel, Beverly Hills, CA. June 5th 2004.

10. UC Irvine/ Orange County Neurological Society Meeting: "Aggressive Treatment of Atherosclerosis in the Ischemic Stroke Patient: Not a moment too soon". Orange County, CA. August 10th 2004
11. UCLA Transcranial and Cerebral Blood Flow Monitoring Fellowship Course. "Monitoring Stroke Risk in Sick Cell Anemia" February 2005; UCLA Medical Center, Los Angeles, CA.
12. UCLA Brain Attack Symposium: "Secondary Stroke Prevention in 2005"; Beverly Hills Hotel, Beverly Hills, CA. May 14th 2005.
13. University of Nevada Las Vegas/ Sunrise Medical Center 2nd Annual Stroke Conference. "Secondary Stroke Prevention. The UCLA PROTECT Program". June 24th 2005.
14. UCLA Transcranial and Cerebral Blood Flow Monitoring Fellowship Course. "Monitoring Stroke Risk in Sick Cell Anemia" July 15th 2005; UCLA Medical Center, Los Angeles, CA.
15. UCLA Transcranial and Cerebral Blood Flow Monitoring Fellowship Course. "Monitoring Stroke Risk in Sick Cell Anemia" September 30th 2005; UCLA Medical Center, Los Angeles, CA
16. UCLA Transcranial and Cerebral Blood Flow Monitoring Fellowship Course. "Monitoring Stroke Risk in Sick Cell Anemia" February 10th 2006; UCLA Medical Center, Los Angeles, CA.
17. UCLA Brain Attack Symposium: "Because One Stroke is Enough....Applying a Multimodality Approach to Vascular Risk Reduction after Stroke", Beverly Hills Hotel, Beverly Hills, CA. May 20th 2006.
18. UCLA Transcranial and Cerebral Blood Flow Monitoring Fellowship Course. "Monitoring Stroke Risk in Sick Cell Anemia" July 14th 2006; UCLA Medical Center, Los Angeles, CA.
19. 6th Annual Science, Innovation and Synergy Conference. "Update on Primary and Vascular Disease Prevention". Seattle, Washington. July 21, 2006
20. UCLA Transcranial and Cerebral Blood Flow Monitoring Fellowship Course. "Monitoring Stroke Risk in Sick Cell Anemia" October 27th 2006; UCLA Medical Center, Los Angeles, CA.
21. UCLA Transcranial and Cerebral Blood Flow Monitoring Fellowship Course. "Monitoring Stroke Risk in Sick Cell Anemia" March 9, 2007; UCLA Medical Center, Los Angeles, CA.
22. UCLA Brain Attack Symposium: "Because One Stroke is Enough: 2007 Scientific Update on Secondary Stroke Prevention", Beverly Hills Hotel, Beverly Hills, CA. May 19th 2007.
23. UCLA Transcranial and Cerebral Blood Flow Monitoring Fellowship Course. "Monitoring Stroke Risk in Sick Cell Anemia" July 18, 2007; UCLA Medical Center, Los Angeles, CA.
24. UCLA Transcranial and Cerebral Blood Flow Monitoring Fellowship Course. "Monitoring Stroke Risk in Sick Cell Anemia" October 12, 2007; UCLA Medical Center, Los Angeles, CA.

25. UCLA Brain Attack Symposium: "Intensive Medical Therapy: Key to Secondary Stroke Prevention", Beverly Hills Hotel, Beverly Hills, CA. May 3rd 2008.
26. UCLA Transcranial and Cerebral Blood Flow Monitoring Fellowship Course. "Monitoring Stroke Risk in Sick Cell Anemia" July 2009; UCLA Medical Center, Los Angeles, CA.
27. UCLA Brain Attack Symposium: "Intensive Medical Therapy: Key to Secondary Stroke Prevention", Tom Bradley-UCLA Center, Los Angeles, CA. May 3rd 2009.

Local Grand Rounds and Noon Lectures

1. Saddleback Memorial Hospital Grand rounds. "Current concepts in ischemic stroke prevention". October 2nd, 2002
2. Olive-view/ UCLA Neurology Grand Rounds: "Neuroprotective Agents in the Treatment of Acute Ischemic Stroke" Los Angeles July, 2002
3. Olive-view/ UCLA Neurology Grand Rounds: "Secondary Stroke Prevention – The UCLA Stroke PROTECT Program" Los Angeles, CA November 2002
4. Olive-view/ UCLA Neurology Grand Rounds: "Hyperhomocystinemia and Stroke", Los Angeles, CA January 2003
5. Olive-view/ UCLA Neurology Grand Rounds: "Symptomatic Intracranial Arterial Disease – The WASID Trial" Los Angeles, CA August 2003
6. Sepulveda VA/UCLA, Los Angeles Internal Medicine Noon lecture: "Stroke Prevention in 2003" May 2003
7. "Acute Stroke Therapies" Neurology Outpatient Lecture Series October 8th, 2003
8. Reed Neurological Research Center, Westwood CA
9. West Los Angeles VA/UCLA, Los Angeles Primary Care Noon lecture: "Secondary Stroke Prevention: Hypertension and Atrial fibrillation" November 18th 2003
10. West Los Angeles VA/UCLA, Los Angeles Primary Care Noon lecture: "Secondary Stroke Prevention: Statins and Lifestyle modification approaches" December 16th 2003
11. UCLA Neurology Grand Rounds: "Bridging the Evidence – Practice Gap in Medical Stroke Prevention: The PROTECT Program", UCLA School of Medicine. Los Angeles, CA. April 14th 2004
12. Olive-View/ UCLA Morning Report Lecture: "Stroke Clinical Pathways and their Rationale" Olive-View/ UCLA Medical Center, CA. May 4th, 2004
13. UCLA Cardiology Grand Rounds: "Early, Aggressive and Feasible – Vascular Risk Reduction in Ischemic Stroke". UCLA Medical Center, Los Angeles, CA. June 28th, 2004
14. Olive-view/ UCLA Neurology Grand Rounds: "An Update on Secondary Stroke Prevention" Los Angeles, CA July 27th 2004
15. Sepulveda VA/UCLA, Los Angeles Internal Medicine Noon lecture: "Stroke Prevention in 2004" August 19th, 2004

16. UCLA Neurology Grand Rounds: "The Metabolic Syndrome and Intracranial Atherosclerotic Disease: A Mind is A Terrible Thing to Waist" UCLA School of Medicine. Los Angeles, CA. March 9th 2005
17. St Johns Medical Center Weekly Lecture Series "Ischemic Stroke Treatment and Prevention" Oxnard, CA. March 23rd 2005
18. Olive View/UCLA Department of Medicine Noon Lecture. "Treatment Options in Preventing Recurrent Stroke". June 21st 2005.
19. UCLA Cardiology Grand Rounds: "The Metabolic Syndrome As A Trigger for Ischemic Stroke". UCLA Medical Center, Los Angeles, CA. June 27th, 2005
20. Olive View/UCLA Department of Medicine Noon Lecture. "Ischemic Stroke and the Metabolic Syndrome: Ominous Pairing?" September 30th 2005, Sylmar, CA.
21. Encino-Tarzana Medical Center Grand Rounds. "Systematic Stroke Prevention". October 11th 2005, Tarzana, California.
22. Olive View/ UCLA Department of Medicine Outpatient Team Lecture. "Secondary Stroke Prevention: Focus on Antithrombotic Therapies" January 27th, 2006, Sylmar, CA
23. UCLA Neurology Outpatient Conference (NOC) lecture: "Multimodality Approach to Vascular Risk Reduction after Stroke". May 17, 2006. Los Angeles, CA.
24. Antelope Valley Hospital Medical Staff Meeting: "Improved Care of the Stroke Patient—How Should Hospitals Like AVH Do It?" June 13th, 2006. Lancaster, CA.
25. Pacifica Hospital Grand Rounds: "Primary and Secondary Stroke Prevention – Pathways of Care" August 30th 2006. Long Beach, CA.
26. Long Beach Community Hospital Grand Rounds: "Secondary Stroke Prevention in 2006" Long Beach, California. December 15th 2006.
27. Long Beach Memorial Hospital Grand Rounds: "Optimizing Secondary Stroke Prevention in 2007: Scientific Evidence and Guideline Recommendations" Long Beach, California. March 15th 2007
28. Santa Barbara Cottage Hospital Surgical Grand Rounds: "Acute Ischemic Stroke Management" Santa Barbara, California. July 18, 2007.
29. American Russia Medical Association Meeting: "Role of Antiplatelet Agents in Ischemic Stroke" Beverly Hills, California August 2007.
30. Professional Resources in Management Education, Inc. (PRIME®) Live Symposium. "Discussing the Evidence in Secondary Stroke Prevention and Management". Woodland Hills, CA. September 26, 2007.
31. Cedars-Sinai Medical Center Neurology Grand Rounds. "Early Intensive Medical Therapy: Key to Secondary Stroke Prevention". Beverly Hills, CA. November 16, 2007.
32. Encino-Tarzana Medical Center Grand Rounds. "Recurrent Stroke Predictors and Magnitude of Risk: A 2007 Update". December 11th 2007, Tarzana, California.
33. Iris Cantor-UCLA Pilot Project Research Luncheon. "Lowering Cholesterol to Prevent Stroke in Women". January 11, 2008, UCLA Faculty Center, Los Angeles, California.

34. Los Robles Medical Center Grand Rounds. "TIA Management". October 17th 2008. Thousand Oaks, California.
35. Tarzana Medical Center Grand Rounds. "Recurrent Stroke Prevention: 2008 Update". October 21st 2008, Tarzana, California.
36. Medical University of South Carolina Progressnotes telepresentation. "Race and Stroke". August 27, 2013. Charleston, SC.
37. Medical University of South Carolina Center for Health Disparities Research/VA HSR&D Grand Rounds. March 3, 2014. Charleston, SC.
38. Medical University of South Carolina. Women Scholars Initiative Workshop - Authorship II. "Art and Science of Successful Authorship in Clinical Research (journal issues and editor perspectives)". July 22, 2015. Charleston, SC.

Stroke Awareness and Community Outreach Lectures

1. American Stroke Association Power to End Stroke - Los Angeles Campaign - Lecture "Stroke in the African American Community" July 16th, 2005, Los Angeles, CA.
2. American Heart/Stroke Associations Western Affiliates Executive Leadership Conference. "Power to End Stroke" Los Angeles, CA. May 24th 2006.
3. American Heart/Stroke Associations. "Stroke in the African American Community and the Power to End Stroke Campaign" Las Vegas, Nevada. August 18th 2006.
4. Bravo Medical Magnet High School. "Los Angeles Unified School District High Blood Pressure Community Project". April 25, 2008, Los Angeles, California.
5. American Heart/Stroke Association (AHA/ASA) "Faces of Power" Event. "Stroke in the African American Community". May 31, 2012, Jacobs Center, San Diego, CA.
6. Congressional staff presentation. "Forecasting the future of stroke". May 22, 2013. Capital Hill. Washington DC.

PUBLICATION/BIBLIOGRAPHY

PEER REVIEW ARTICLES

A) Lead or Senior Authorship Only:

1. **Ovbiagele B**, Kidwell CS, Starkman S, Saver JL. Neuroprotective agents for the treatment of acute ischemic stroke. *Curr Neurol Neurosci Rep*. 2003;3:9-20.

2. **Ovbiagele B**, Kidwell CS, Starkman S, Saver JL. Potential Role of Neuroprotective Agents in the Treatment of Patients with Acute Ischemic Stroke. *Curr Treat Options Neurol*. 2003;5:367-375.
3. **Ovbiagele B**, Kidwell CS, Saver JL. Epidemiological impact in the United States of a tissue-based definition of transient ischemic attack. *Stroke*. 2003;34:919-24.
4. **Ovbiagele B**, Saver JL, Fredieu A, Suzuki S, McNair N, Dandekar A, Razinia T, Kidwell CS. PROTECT: a coordinated stroke treatment program to prevent recurrent thromboembolic events. *Neurology*. 2004;63:1217-22.
5. **Ovbiagele B**, Saver JL, Fredieu A, Suzuki S, Selco S, Rajajee V, McNair N, Razinia T, Kidwell CS. In-hospital initiation of secondary stroke prevention therapies yields high rates of adherence at follow-up. *Stroke*. 2004;35:2879-83.
6. Bhidayasiri R, Hathout GM, Heyming TW, **Ovbiagele B**. Cerebellar arteriovenous malformation presenting with bilateral proptosis mimicking caroticocavernous fistula. *Br J Hosp Med*. 2004;65:690-1.
7. **Ovbiagele B**, Kidwell CS, Saver J. Expanding indications for statins in cerebral ischemia: a quantitative study. *Arch Neurol*. 2005;62:67-72. *{With Editorial Commentary}*
8. Cardenas D, Mishra SK, Ohanian AG, **Ovbiagele B**. Successive yet distinct episodes of isolated ophthalmoplegia associated with anti-GQ1b antibody. *Neurology*. 2005;65:163.
9. Suzuki S, Kidwell CS, Starkman S, Saver JL, Duckwiler G, Vinuela F, **Ovbiagele B**. Use of multimodal MRI and novel endovascular therapies in a patient ineligible for intravenous tissue plasminogen activator. *Stroke*. 2005;36:e77-9.
10. Bower CM, Morgan L, **Ovbiagele B**. A patient with left ventricular thrombus and recurrent stereotypic TIAs. *Neurology*. 2005;65:492-3.
11. Kremen SA, Wu MN, **Ovbiagele B**. Hemopericardium following Intravenous Thrombolysis for acute ischemic stroke. *Cerebrovasc Dis*. 2005;20:478-9.
12. **Ovbiagele B**, Saver JL. The smoking-thrombolysis paradox and acute ischemic stroke. *Neurology*. 2005;65:293-5. *{With Editorial Commentary}*
13. **Ovbiagele B**, Hills NK, Saver JL, Johnston SC. Antihypertensive medications prescribed at discharge after an acute ischemic cerebrovascular event. *Stroke*. 2005;36:1944-7.

14. **Ovbiagele B**, Kidwell CS, Selco S, Razinia T, Saver JL. Treatment adherence rates one year after initiation of a systematic hospital-based stroke prevention program. *Cerebrovasc Dis*. 2005;20:280-2.
15. **Ovbiagele B**, Kidwell CS, Starkman S, Selco SL, Rajajee V, Razinia T, Saver JL. Angiotensin 2 type 2 receptor activity and ischemic stroke severity. *Neurology*. 2005;65:851-4.
16. **Ovbiagele B**, Weir CJ, Saver JL, Muir KW, Lees KR. Effect of smoking status on outcome after acute ischemic stroke. *Cerebrovasc Dis*. 2006;21:260-5.
17. **Ovbiagele B**, Hills NK, Saver JL, Johnston SC. Secondary-prevention drug prescription in the very elderly after ischemic stroke or TIA. *Neurology*. 2006;66:313-8.
18. **Ovbiagele B**, Saver JL, Bang H, Chambless LE, Nassief A, Minuk J, Toole JF, Crouse JR. Statin treatment and national cholesterol guideline adherence among ischemic stroke survivors. *Neurology* 2006;66:1164-70. *{With Editorial Commentary}*
19. **Ovbiagele B**, Saver JL, Lynn MJ, Chimowitz M. Impact of metabolic syndrome on prognosis of symptomatic intracranial atherostenosis. *Neurology* 2006;66:1344-9.
20. **Ovbiagele B**, Liebeskind DS, Starkman S, Sanossian S, Kim D, Razinia T, Saver JL. Are elevated admission calcium levels associated with better outcomes after ischemic stroke? *Neurology* 2006;67:170-73.
21. Sanossian N, Saver J, Rajajee V, Selco S, Kim D, Razinia T, **Ovbiagele B**. Premorbid antiplatelet use and ischemic stroke outcomes. *Neurology*. 2006;66:319-23.
22. Shah SH, Liebeskind DS, Saver JL, Starkman S, Vinuela P, Duckwiler G, Jahan R, Kim D, Sanossian N, Vespa PM, **Ovbiagele B**. Influence of gender on outcomes after intraarterial thrombolysis for acute ischemic stroke. *Neurology* 2006;66:1745-6.
23. Sanossian N, Saver JL, Liebeskind DS, Kim D, Razinia T, **Ovbiagele B**. Achieving target cholesterol goals after stroke: is in-hospital statin initiation the key? *Arch Neurol*. 2006;63:1052-1054.
24. Cardenas D, **Ovbiagele B**. Arterial dissection and cerebral venous thrombosis in sickle cell trait. *Br J Hosp Med*. 2006;67:380-81.

25. **Ovbiagele B**, Saver JL. Ensuring management of vascular risk factors after stroke. *Reviews in Neurological Diseases*. 2006;3:93-100.
26. Sanossian N, **Ovbiagele B**. Multimodality Stroke Prevention. *Neurologist*. 2006;12:14-31.
27. **Ovbiagele B**. The Emergency Department: First Line of Defense in Preventing Secondary Stroke. *Acad Emerg Med*. 2006;13:215-22.
28. **Ovbiagele B**, Saver JL. Cerebral white matter hyperintensities on MRI: current concepts and therapeutic implications. *Cerebrovasc Dis*. 2006;22:83-90.
29. Fogel B, Cardenas D, **Ovbiagele B**. MRI abnormalities in the corpus callosum of a patient with neuropsychiatric lupus. *The Neurologist*. 2006;12:271-273.
30. Sanossian N, Saver JL, Kim D, Razinia T, **Ovbiagele B**. Do high density lipoprotein cholesterol levels influence stroke severity? *J Stroke Cerebrovasc Dis*. 2006;15:187-89.
31. Sanossian N, Ohanian AG, Saver JL, Kim LI, **Ovbiagele B**. Frequency and determinants of nonpublication of research in the stroke literature. *Stroke*. 2006;37:2588-92.
32. **Ovbiagele B**, Hills NK, Saver JL, Johnston SC. Lipid assessment and treatment patterns in hospitalized TIA and ischemic stroke patients. *Journal of Hospital Medicine*. 2006;1:214-220.
33. **Ovbiagele B**, Saver JL, Sanossian N, Salamon N, Villablanca P, Alger JR, Razinia T, Kim D, Liebeskind DS. Predictors of cerebral microbleeds in acute ischemic stroke and TIA patients. *Cerebrovasc Dis*. 2006;22:378-83.
34. **Ovbiagele B**, Hills NK, Saver JL, Johnston SC. Frequency and Determinants of Pneumonia and Urinary Tract Infection during Stroke Hospitalization. *J Stroke Cerebrovasc Dis*. 2006;15:209-13.
35. **Ovbiagele B**, Hills NK, Saver JL, Johnston SC. Are Racial Differences in Antihypertensives Responsiveness Reflected in Usage after Stroke? *J Stroke Cerebrovasc Dis*. 2006;15:260-65.
36. **Ovbiagele B**, Levine S. Addressing Racial and Ethnic Disparities in Stroke: the time is now. *Neurology* 2006;67:1328-9.
37. Bang OY, Saver JL, Liebeskind DS, Starkman S, Villablanca P, Salamon N, Buck B, Ali L, Restrepo L, Vinuela P, Duckwiler G, Jahan R, Razinia T,

Ovbiagele B. Cholesterol level and symptomatic hemorrhagic transformation after ischemic stroke thrombolysis. *Neurology*. 2007;68:737-42. *{With Editorial Commentary}*

38. Razinia T, Saver JL, Liebeskind DS, Buck B, Ali LK, **Ovbiagele B.** Body Mass Index and Hospital Discharge Outcomes after Ischemic Stroke. *Arch Neurol*. 2007;64:388-91.
39. Viehman JA, Saver JL, Liebeskind DS, Starkman S, Buck B, Ali LK, Razinia T, **Ovbiagele B.** Utility of Urinalysis in Discriminating Cardioembolic Stroke Mechanism. *Arch Neurol*. 2007;64:667-70.
40. Buck BH, Liebeskind DS, Saver JL, Bang OY, Starkman S, Ali LK, Kim D, Villablanca JP, Salamon N, Yun SW, Razinia T, **Ovbiagele B.** Higher Serum Calcium Levels are Associated with Smaller Infarct Volumes in Acute Ischemic Stroke. *Arch Neurol*. 2007;64:1287-91.
41. Towfighi A, Saver JL, Engelhardt R, **Ovbiagele B.** A Midlife Stroke Surge Among Women in the United States. *Neurology* 2007;69:1898-904. *{With Editorial Commentary}*
42. **Ovbiagele B,** Saver JL Starkman S, Kim D, Ali LK, Jahan R, Duckwiler G, Vinuela F, Pineda S, Liebeskind DS. Statin Enhancement of Collateralization in Acute Stroke. *Neurology*. 2007;68:2129-31.
43. **Ovbiagele B,** Sachdeva S. Preventing Another Event: Role of the Hospitalist in Discharge Stroke Prevention. *Journal of Hospital Medicine*. 2007; 2007;2:31-8.
44. Sanossian N, Saver JL, Navab M, **Ovbiagele B.** High Density Lipoprotein Cholesterol: An Emerging Target for Stroke Treatment. *Stroke*. 2007;38:1104-9.
45. Alberts MJ, **Ovbiagele B.** Current strategies for ischemic stroke prevention: role of multimodal combination therapies. *Journal of Neurology*. 2007;254:1414-26.
46. **Ovbiagele B,** Lynn MJ, Saver JL, Chimowitz M. Leukocyte Count and Vascular Risk in Symptomatic Intracranial Atherosclerosis. *Cerebrovasc Dis*. 2007;24:283-288.
47. **Ovbiagele B,** Saver J. Intensive statin therapy after stroke or transient ischemic attack: a sparkling success? *Stroke* 2007; 38:1110-2.

48. **Ovbiagele B**, Buck BH, Starkman S, Liebeskind DS, Bang OY, Ali LK, Villablanca JP, Salamon N, Yun SW, Pineda S, Saver JL. Prior Antiplatelet Use and Infarct Volume in Ischemic Stroke. *J Neurol Sci*. 2008;264:140-4.
49. **Ovbiagele B**, Hutchison P, Handschumacher L, Coleman A, Gutierrez M, Yellin-Mednick S, Beanes S, Cooper EM, Pratt FD. Educating and Mobilizing Youths to Detect Undiagnosed Elevated Blood Pressure: Searching for the Silent Killer. *Ethn Dis*. 2008;18:84-8.
50. **Ovbiagele B**, Drogan O, Koroshetz W, Fayad P, Saver J. Outpatient Practice Patterns Following Stroke Hospitalization Among Neurologists. *Stroke* 2008;39(6):1850-4.
51. Buck BH, Liebeskind DS, Saver JL, Yun SW, Bang OY, Starkman S, Ali LK, Kim D, Villablanca JP, Salamon N, Razinia T, **Ovbiagele B**. Early Neutrophilia is Associated with Volume of Ischemic Tissue in Acute Stroke. *Stroke*. 2008;39:355-60.
52. Rahiman A, Saver J, Selco SL, Razinia T, Buxton W, Porter V, **Ovbiagele B**. In-hospital Initiation of Secondary Prevention is associated with Improved Outcomes at 3 months. *J Stroke Cerebrovasc Dis* 2008;17:5-8.
53. Bang OY, Saver JL, Liebeskind DS, Pineda S, **Ovbiagele B**. Association of Serum Lipid Indices with Large Artery Atherosclerotic Stroke *Neurology*. 2008;70:841-8477.
54. Pineda S, Bang OY, Saver JL, Starkman S, Yun SW, Liebeskind DS, Kim D, Ali LK, Shah SH, **Ovbiagele B**. Association of serum bilirubin with ischemic stroke outcomes. *J Stroke Cerebrovasc Dis*. 2008;17:147-52.
55. Towfighi A, Saver JL, Engelhardt R, **Ovbiagele B**. Factors Associated with the Steep Rise in Late Midlife Stroke Occurrence among US Men. *J Stroke Cerebrovasc Dis*. 2008;17(4):165-8.
56. Shah SH, Engelhardt R, **Ovbiagele B**. Patterns of Complementary and Alternative Medicine Use Among United States Stroke Survivors. *J Neurol Sci*. 2008;271(1-2):180-5.
57. Sanossian N, **Ovbiagele B**. Drug Insight: translating evidence on statin therapy into clinical benefits. *Nature Clinical Practice Neurology*. 2008;4:43-49.
58. Towfighi A, **Ovbiagele B**. Metabolic syndrome and stroke. *Curr Diab Rep*. 2008;8:37-41.

59. **Ovbiagele B.** Antiplatelet Therapy in TIA Management: Overview and Evidence-based Rationale. *J Emerg Med.* 2008;34(4):389-96.
60. **Ovbiagele B.** Microalbuminuria: Risk Factor and Potential Therapeutic Target for Stroke? *J Neurol Sci.* 2008;271(1-2):21-8.
61. Towfighi A, **Ovbiagele B.** Partial PPAR-Agonist Angiotensin Receptor Blockers: Potential Multipronged Strategy in Stroke Prevention. *Cerebrovasc Dis.* 2008;26(2):106-112.
62. Sanossian N, **Ovbiagele B.** The risk of stroke within a week of minor stroke or transient ischemic attack. *Expert Opin Pharmacother.* 2008;9(12):2069-76.
63. **Ovbiagele B.** Pessin Award Lecture 2008: Lessons from the Stroke PROTECT Program. *J Neurol Sci.* 2008;275(1-2):1-6.
64. **Ovbiagele B,** Cruz-flores S, Lynn MJ, Chimowitz M. Early Stroke Risk after TIA among Individuals with Symptomatic Intracranial Artery Stenosis. *Arch Neurol.* 2008;65(6):733-7.
65. **Ovbiagele B.** Impairment of Glomerular Filtration Rate or Glomerular Filtration Barrier and Occurrence of Stroke. *Arch Neurol.* 2008;65(7):934-8.
66. **Ovbiagele B,** Starkman S, Teal P, Lyden P, Kaste M, Davis SM, Hacke W, Fierus M, Saver JL; VISTA Investigators. Serum Calcium as Prognosticator in Ischemic Stroke. *Stroke.* 2008;39(8):2231-6.
67. **Ovbiagele B.** Potential role of curcumin in stroke prevention. *Expert Rev Neurother.* 2008;8(8):1175-6.
68. Sanossian N, **Ovbiagele B.** Probing Racial and Regional Disparities in Stroke Mortality: Same Problem, Different Solutions? *Annals of Neurology* 2008;64(5):483-4
69. **Ovbiagele B,** McNair N, Saver J. A Care Pathway To Boost Influenza Vaccination Rates Among Acute Ischemic Stroke and TIA Inpatients. *J Stroke Cerebrovasc Dis.* 2009;18(1):38-40.
70. **Ovbiagele B.** Association of Ankle Brachial Index level with Stroke. *J Neurol Sci.* 2009;276(1-2):14-7.
71. Bang OY, Saver JL, Liebeskind DS, Lee PH, Sheen SS, Yoon SR, Yun SW, Kim GM, Chung CS, Lee KH, **Ovbiagele B.** Age-Distinct Predictors of Symptomatic Cerebrovascular Atherosclerosis. *Cerebrovasc Dis.* 2009;27(1):13-21.

72. Sanossian N, Gatto N, **Ovbiagele B**. Patterns of Influenza Vaccination among Stroke Survivors. *Neuroepidemiology*. 2009;32(3):165-70.
73. Ani C, **Ovbiagele B**. Elevated Red Blood Cell Distribution Width Predicts Mortality in Persons with Known Stroke. *J Neurol Sci*. 2009;277(1-2):103-8
74. Ling G, **Ovbiagele B**. Oral antiplatelet therapy in the secondary prevention of atherothrombotic events. *Am J Cardiovasc Drugs*. 2009;9(3):197-209.
75. Sanossian N, **Ovbiagele B**. Prevention and management of stroke in very elderly patients. *Lancet Neurology*. 2009 Oct 1. {With Editorial Commentary}
76. Song S, **Ovbiagele B**. Management of risk factors for accelerated atherosclerosis. *Curr Treat Options Neurol*. 2009 Nov;11(6):460-72.
77. **Ovbiagele B**. Pathways and tools of Stroke PROTECT: a hospital-based recurrent stroke prevention program. *Crit Pathw Cardiol*. 2009;8(4):151-5.
78. Bang OY, Saver JL, Liebeskind DS, Pineda S, Yun SW, **Ovbiagele B**. Impact of metabolic syndrome on distribution of cervicocephalic atherosclerosis: data from a diverse race-ethnic group. *J Neurol Sci*. 2009;284(1-2):40-5.
79. Zurrú MC, Alonzo C, Brescacin L, Romano M, Cámara LA, Waisman G, Cristiano E, **Ovbiagele B**. Recent respiratory infection predicts atherothrombotic stroke: case-control study in a Buenos Aires healthcare system. *Stroke*. 2009;40(6):1986-90.
80. Towfighi A, **Ovbiagele B**. The impact of body mass index on mortality after stroke. *Stroke*. 2009;40(8):2704-8.
81. **Ovbiagele B**, Liebeskind DS, Kim D, Ali LK, Pineda S, Saver JL. Optimizing Screening and Management of Asymptomatic Coronary Artery Disease in Patients With Stroke and Patients With Transient Ischemic Attack. *Stroke*. 2009 Aug 13.
82. Towfighi A, Zheng L, **Ovbiagele B**. Sex-specific trends in midlife coronary heart disease risk and prevalence. *Arch Intern Med*. 2009 Oct 26;169(19):1762-6. {With Editorial Commentary}
83. **Ovbiagele B**, Sanossian N, Liebeskind DS, Kim D, Ali LK, Pineda S, Saver JL. Indices of kidney dysfunction and discharge outcomes in hospitalized stroke patients without known renal disease. *Cerebrovasc Dis*. 2009;28(6):582-8.

84. Ani C, **Ovbiagele B**. Relation of baseline presence and severity of renal disease to long-term mortality in persons with known stroke. *J Neurol Sci*. 2010 Jan 15;288(1-2):123-8.
85. **Ovbiagele B**. Optimizing vascular risk reduction in the stroke patient with atherothrombotic disease. *Med Princ Pract*. 2010;19(1):1-12.
86. **Ovbiagele B**, Saver JL. Day-90 acute ischemic stroke outcomes can be derived from early functional activity level. *Cerebrovasc Dis*. 2010;29(1):50-6.
87. **Ovbiagele B**, Campbell S, Faiz A, Chambless LE. Relationship between Non-Specific Prescription Pill Adherence and Ischemic Stroke Outcomes. *Cerebrovasc Dis*. 2010;29(2):146-53.
88. **Ovbiagele B**, Liebeskind DS, Pineda S, Saver JL. Strong independent correlation of proteinuria with cerebral microbleeds in patients with stroke and transient ischemic attack. *Arch Neurol*. 2010 Jan;67(1):45-50.
89. **Ovbiagele B**. 'Al Pie De La Letra'. Crafting a Report Card for Elderly Spanish-Only-Speaking Patients With Stroke. *Stroke*. 2010 Feb 18.
90. **Ovbiagele B**. Pathways to Further Boost Treatment Rates and Clinical Outcomes in Hospitalized Stroke Patients. *Crit Pathw Cardiol*. 2010 Mar;9(1):8-13
91. Hong JM, Bang OY, Chung CS, Joo IS, Gwag BJ, **Ovbiagele B**. Influence of Recanalization on Uric Acid Patterns in Acute Ischemic Stroke. *Cerebrovasc Dis* 2010;29:431-439.
92. **Ovbiagele B**. Relation of New and Old Formulas for Estimating Creatinine Clearance Among Stroke Survivors. *Med Princ Pract*. 2010;19(4):319-20.
93. **Ovbiagele B**, Liebeskind DS, Kim D, Ali LK, Pineda S, Saver JL. Prognostic Value of Framingham Cardiovascular Risk Score in Hospitalized Stroke Patients. *J Stroke Cerebrovasc Dis*. 2010. Jul 23. [Epub ahead of print]
94. Lee M, **Ovbiagele B**. Navigating the Gray Zones of Stroke Management for a Graying Population. *Cerebrovasc Dis* 2010;29(6):523-7.
95. **Ovbiagele B**, Pineda S, Saver JL. Renal Dysfunction and Discharge Destination among Intracerebral Hemorrhage Patients. *J Stroke Cerebrovasc Dis*. 2010. E-pub May 14, 2010.
96. Abcede H, **Ovbiagele B**. Update on Antithrombotic Therapy for Stroke Prevention in Atrial Fibrillation. *Curr Treat Options Cardiovasc Med*. 2010;12(3):250-260.

97. Sanossian N, Gatto N, **Ovbiagele B**. Subpar Utilization of Dental Care among Americans with a History of Stroke. *J Stroke Cerebrovasc Dis*. 2010. Jul 23. [Epub ahead of print]

98. Froehler M, **Ovbiagele B**. Therapeutic hypothermia for acute ischemic stroke. *Expert Rev Cardiovasc Ther*. 2010;8(4):593-603.

(b) (4)

100. **Ovbiagele B**. Potential role of Group Clinics to Boost Outcomes among Elderly Spanish-only Speaking Stroke Patients. *Crit Pathw Cardiol*. 2010;9(2):88-93.

101. Towfighi A, Zheng L, **Ovbiagele B**. Weight of the Obesity Epidemic: Rising Stroke Rates Among Middle-Aged Women in the United States. *Stroke* 2010;41(7):1371-5..

102. **Ovbiagele B**. National Gender Trends in Hospital-based Stroke Rates. *J Stroke Cerebrovasc Dis*. 2010. Aug 17. [Epub ahead of print]

103. **Ovbiagele B**, Hutchison P, Handschumacher L, Coleman A, Gutierrez M, Yellin-Mednick S, Beanes S, Cooper EM, Shields L, Horowitz D, Moore C. Urban High School Students can Successfully Screen for High Blood Pressure in their Community. *Ethn Dis*. 2010;20(3):223

104. **Ovbiagele B**, Schwamm L, Smith EE, Hernandez AF, Olson DM, Pan W, Fonarow G, Saver JL. Recent Nationwide Trends in Discharge Statin Treatment of Hospitalized Stroke Patients. *Stroke* 2010;41(7):1508-13.

105. **Ovbiagele B**. Nationwide Trends in In-hospital Mortality among Stroke Patients. *Stroke*. 2010;41(8):1748-54.

106. **Ovbiagele B**. Hospital-based Stroke Diagnoses among the Oldest Old in the United States: 1997-2006. *Stroke*. 2010;41(8):1820-2.

107. **Ovbiagele B**, Lyden P, Saver JL. Disability Status at One month is A Reliable Proxy for Final Ischemic Stroke Outcome. *Neurology*. 2010. Neurology. 2010;75(8):688-92.

108. Lee M, Saver JL, Chang KH, **Ovbiagele B**. Level of Albuminuria and Risk of Stroke: Systematic Review and Meta-analysis. *Cerebrovasc Dis*. 2010;30(5):464-469

109. Towfighi A, Markovic D, **Ovbiagele B**. Pronounced association of elevated serum homocysteine with stroke in subgroups of individuals: A nationwide study. *J Neurol Sci*. 2010 Aug 30. [Epub ahead of print]
110. **Ovbiagele B**, Schwamm L, Smith EE, Hernandez AF, Olson DM, Pan W, Fonarow G, Saver JL. Patterns and Predictors of Discharge Statin Prescription among Hospitalized Intracerebral Hemorrhage Patients. *Stroke*. 2010. Aug 19. [Epub ahead of print]
111. Lee M, Saver JL, Chang KH, Liao HW, Chang SC, **Ovbiagele B**. Impact of Microalbuminuria on Incident Stroke: A Meta-analysis. *Stroke*. 2010;41(11):2625-31
112. Lee M, Saver JL, Chang KH, Liao HW, Chang SC, **Ovbiagele B**. Low glomerular filtration rate and stroke risk: a meta-analysis. *BMJ*. 2010;341:c4249. doi: 10.1136/bmj.c4249
113. Towfighi A, Markovic D, **Ovbiagele B**. Persistent Sex Disparity in Midlife Stroke Prevalence in the United States. *Cerebrovasc Dis*. 2011;31(4):322-8.
114. Lee M, Saver JL, Huang WH, Chow J, Chang KC, **Ovbiagele B**. Impact of Elevated Cystatin C Level on Cardiovascular Disease Risk in Predominantly High Cardiovascular Risk Populations: A Meta-analysis. *Circ Cardiovasc Qual Outcomes*. 2010;3(6):675-83.
115. **Ovbiagele B**. Is Midlife Spread causing a Midlife Stroke Crisis for Women in the USA? *Expert Rev Cardiovasc Ther*. 2010;8(10):1355-1357.
116. **Ovbiagele B**, Markovic D, Towfighi A. Recent Age- and Sex-Specific Trends in Mortality during Stroke Hospitalization in the United States. *Int J Stroke*. 2011 Oct;6(5):379-87
117. **Ovbiagele B**, Nath A. Increasing Incidence of Ischemic Stroke in Patients with HIV infection. *Neurology* 2011;76(5):444-50
118. **Ovbiagele B**, Hutchison P, Handschumacher L, Coleman A, Gutierrez M, Yellin-Mednick S, Beanes S, Cooper EM, Shields L, Horowitz D, Moore C. Impact of an urban community hypertension screening program on participating high school students. *Ethn Dis*. 2011; Winter;21(1):68-73.
119. Ani C, Pan D, Martins D, **Ovbiagele B**. Age- and sex-specific in-hospital mortality after myocardial infarction in routine clinical practice. *Cardiol Res Pract*. 2010 Dec 28;2010:752765.
120. **Ovbiagele B**, Markovic D, Fonarow GC. Recent US Patterns and Predictors of Prevalent Diabetes among Acute Myocardial Infarction Patients. *Cardiol Res Pract*. 2011 Apr 7;2011:145615.

121. Lee M, **Ovbiagele B**. Vascular events after stroke: terutroban fails to PERFORM. Lancet. 2011 Jun 11;377(9782):1980-2.
122. Lee M, Saver JL, Towfighi A, Chow J, **Ovbiagele B**. Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: A meta-analysis. Atherosclerosis. 2011 Aug;217(2):492-8.
123. **Ovbiagele B**, Nguyen-Huynh MN. Stroke epidemiology: advancing our understanding of disease mechanism and therapy. Neurotherapeutics. 2011 Jul;8(3):319-29.
124. Meyer DM, Eastwood JA, Compton MP, Glyls K, Zivin JA, **Ovbiagele B**. Sex differences in antiplatelet response in ischemic stroke. Womens Health (Lond Engl). 2011 Jul;7(4):465-74.
125. **Ovbiagele B**. Sex-Specific Time Trends in Very Elderly Patients (Aged ≥ 80 Years) Hospitalized with Myocardial Infarction. Med Princ Pract. 2011 Oct 21. [Epub ahead of print]
126. Neil W, **Ovbiagele B**. Intravenous thrombolysis in ischemic stroke patients with intracranial neoplasms: two cases and a literature review. Case Report Med. 2011;2011:503758.
127. Lee M, Saver JL, Hong KS, Hao Q, **Ovbiagele B**. Does achieving an intensive versus usual blood pressure level prevent stroke? Ann Neurol. 2011 Jun 2. doi: 10.1002/ana.22496.
128. Towfighi A, Tai W, Markovic D, **Ovbiagele B**. Sex-Specific Temporal Trends in In-Hospital Mortality After Stroke Among Middle-Age Individuals in the United States. Stroke. 2011 Oct;42(10):2740-5.
129. Towfighi A, Markovic D, **Ovbiagele B**. National Gender-Specific Trends in Myocardial Infarction Hospitalization Rates Among Patients Aged 35 to 64 Years. Am J Cardiol. Am J Cardiol. 2011 Oct 15;108(8):1102-7
130. Towfighi A, Markovic D, **Ovbiagele B**. Recent patterns of sex-specific midlife stroke hospitalization rates in the United States. Stroke. 2011 Nov;42(11):3029-33.
131. Lee M, Saver JL, Chang B, Chang KH, Hao Q, **Ovbiagele B**. Presence of baseline prehypertension and risk of incident stroke: a meta-analysis. Neurology. 2011 Oct 4;77(14):1330-7.

132. Towfighi A, Markovic D, **Ovbiagele B**. Impact of a healthy lifestyle on all-cause and cardiovascular mortality after stroke in the USA. *J Neurol Neurosurg Psychiatry*. 2011 Oct 21.
133. **Ovbiagele B**, Bath PM, Cotton D, Vinisko R, Diener HC. Obesity and Recurrent Vascular Risk After a Recent Ischemic Stroke. *Stroke*. 2011 Sep 29. [Epub ahead of print] *{With Editorial Commentary}*
134. Lee M, Saver JL, Hong KS, Hao Q, Chow J, **Ovbiagele B**. Renin-Angiotensin System Modulators Modestly Reduce Vascular Risk in Persons With Prior Stroke. *Stroke*. 2011 Nov 3. [Epub ahead of print]
135. **Ovbiagele B**, Diener HC, Yusuf S, Martin RH, Cotton D, Vinisko R, Donnan GA, Bath PM; PROFESS Investigators. Level of systolic blood pressure within the normal range and risk of recurrent stroke. *JAMA*. 2011 Nov 16;306(19):2137-44. *{With Editorial Commentary}*
136. **Ovbiagele B**, Guzik A. Patient management problem-preferred responses. *Continuum (Minneap Minn)*. 2011 Dec;17(6 2ndary Stroke Prevention):1392-408.
137. **Ovbiagele B**, Guzik A. Patient management problem. *Continuum (Minneap Minn)*. 2011 Dec;17(6 2ndary Stroke Prevention):1385-91.
138. Lee M, Saver JL, Hong KS, Song S, Chang KH, **Ovbiagele B**. Effect of pre-diabetes on future risk of stroke: meta-analysis. *BMJ*. 2012 Jun 7;344:e3564.
139. **Ovbiagele B**. Low-Normal Systolic Blood Pressure and Secondary Stroke Risk. *J Stroke Cerebrovasc Dis*. 2012 Jan 12.
140. Towfighi A, Markovic D, **Ovbiagele B**. Current national patterns of comorbid diabetes among acute ischemic stroke patients. *Cerebrovasc Dis*. 2012;33(5):411-8.
141. Towfighi A, Markovic D, **Ovbiagele B**. Temporal trends in risk of future cardiac events among stroke survivors in the United States. *Int J Stroke*. 2012 Apr;7(3):207-12.
142. Pearce D, Ani C, Espinosa-Silva Y, Clark R, Fatima K, Rahman M, Diebolt E, **Ovbiagele B**. Comparison of In-Hospital Mortality From Acute Myocardial Infarction in HIV Sero-Positive Versus Sero-Negative Individuals. *Am J Cardiol*. 2012 Jul 2.

143. Towfighi A, Markovic D, **Ovbiagele B**. Utility of Framingham Coronary Heart Disease Risk Score for predicting cardiac risk after stroke. *Stroke*. 2012 Nov;43(11):2942-7.
144. Lee M, Saver JL, Hong KS, Wu HC, **Ovbiagele B**. Risk of intracranial hemorrhage with protease-activated receptor-1 antagonists. *Stroke*. 2012 Dec;43(12):3189-95.
145. Selco SL, Markovic D, **Ovbiagele B**. Cranial neurosurgery procedure utilization among patients with acute ischemic stroke. *J Stroke Cerebrovasc Dis*. 2013 Nov;22(8):e293-300.
146. Sanossian N, Djabiras C, Mack WJ, **Ovbiagele B**. Trends in cancer diagnoses among inpatients hospitalized with stroke. *J Stroke Cerebrovasc Dis*. 2013 Oct;22(7):1146-50.
147. Lee M, Saver JL, Hong KS, Wu HC, **Ovbiagele B**. Risk-benefit profile of warfarin versus aspirin in patients with heart failure and sinus rhythm: a meta-analysis. *Circ Heart Fail*. 2013 Mar;6(2):287-92.
148. Lee M, Markovic D, **Ovbiagele B**. Impact and interaction of low estimated GFR and B vitamin therapy on prognosis among ischemic stroke patients: the Vitamin Intervention for Stroke Prevention (VISP) trial. *Am J Kidney Dis*. 2013 Jul;62(1):52-7.
149. Towfighi A, Markovic D, **Ovbiagele B**. Sex differences in revascularization interventions after acute ischemic stroke. *J Stroke Cerebrovasc Dis*. 2013 Nov;22(8):e347-53.
150. **Ovbiagele B**, Wing JJ, Menon RS, Burgess RE, Gibbons MC, Sobotka I, German L, Shara NM, Fernandez S, Jayam-Trouth A, Edwards DF, Kidwell CS. Association of Chronic Kidney Disease With Cerebral Microbleeds in Patients With Primary Intracerebral Hemorrhage. *Stroke*. 2013 Jul 11.
151. **Ovbiagele B**, Ernstom K, Markovic D, Raman R. Trends in Antihypertensive Drug Prescription Patterns among Ambulatory Stroke Patients in the United States, 2000-2009. *J Stroke Cerebrovasc Dis*. 2013 Jul 17.

152. Saposnik G, Reeves MJ, Johnston SC, Bath PM, **Ovbiagele B**; on behalf of the VISTA Collaboration. Predicting Clinical Outcomes After Thrombolysis Using the iScore: Results From the Virtual International Stroke Trials Archive. *Stroke*. 2013 Jul 25.
153. **Ovbiagele B**, Bath PM, Cotton D, Sha N, Diener HC; for the PROFESS Investigators. Low Glomerular Filtration Rate, Recurrent Stroke Risk, and Effect of Renin-Angiotensin System Modulation. *Stroke*. 2013 Aug 29. [Epub ahead of print]
154. Huang YC, Wu YL, Lee MH, Lee JD, Wu CY, Hsu HL, Lin YH, Huang YC, Huang WH, Weng HH, Yang JT, Lee M, **Ovbiagele B**. Association of Renal Biomarkers with 3-Month and 1-Year Outcomes among Critically Ill Acute Stroke Patients. *PLoS One*. 2013 Sep 13;8(9):e72971.
155. Lee M, Saver JL, Hong KS, Rao NM, Wu YL, **Ovbiagele B**. Risk-benefit profile of long-term dual- versus single-antiplatelet therapy among patients with ischemic stroke: a systematic review and meta-analysis. *Ann Intern Med*. 2013 Oct 1;159(7):463-70.
156. Owolabi MO, Akinyemi RO, Hurst S, Arulogun O, Olaniyan O, Gebregziabher M, Salako BL, **Ovbiagele B**. Tailored Hospital-based Risk Reduction to Impede Vascular Events After Stroke (THRIVES) Study: Qualitative Phase Protocol. *Crit Pathw Cardiol*. 2014 Mar;13(1):29-35.
157. Gorelick PB, Goldstein LB, **Ovbiagele B**. New Guidelines to Reduce Risk of Atherosclerotic Cardiovascular Disease: Implications for Stroke Prevention in 2014. *Stroke*. 2014 Feb 20. [Epub ahead of print].
158. Towfighi A, Markovic D, **Ovbiagele B**. Consistency of Blood Pressure Control After Ischemic Stroke: Prevalence and Prognosis. *Stroke*. 2014 Mar 27.
159. **Ovbiagele B**, Goldstein LB, Amarenco P, Messig M, Sillesen H, Callahan A 3rd, Hennerici MG, Zivin J, Welch KM; SPARCL Investigators. Prediction of major vascular events after stroke: the stroke prevention by aggressive reduction in cholesterol levels trial. *J Stroke Cerebrovasc Dis*. 2014 Apr;23:778-84.

160. Park JH, Kwon HM, Lee J, Kim DS, **Ovbiagele B**. Association of intracranial atherosclerotic stenosis with severity of white matter hyperintensities. *Eur J Neurol*. Apr 9. 2014.
161. Towfighi A, Arshi B, Markovic D, **Ovbiagele B**. Homocysteine-Lowering Therapy and Risk of Recurrent Stroke, Myocardial Infarction and Death: The Impact of Age in the VISP Trial. *Cerebrovasc Dis*. 2014 Apr 15;37:263-267.
162. **Ovbiagele B**, Reeves MJ, Nasiri M, Johnston SC, Bath PM, Saposnik G; for the VISTA-Acute Collaboration Steering Committee. A Simple Risk Index and Thrombolytic Treatment Response in Acute Ischemic Stroke. *JAMA Neurol*. 2014 May 5. doi: 10.1001/jamaneurol.2014.689. [Epub ahead of print]
163. **Ovbiagele B**, Schwamm LH, Smith EE, Grau-Sepulveda MV, Saver JL, Bhatt DL, Hernandez AF, Peterson ED, Fonarow GC. Patterns of care quality and prognosis among hospitalized ischemic stroke patients with chronic kidney disease. *J Am Heart Assoc*. 2014 Jun 5;3(3):e000905.
164. Ellis C, McGrattan K, Mauldin P, **Ovbiagele B**. Costs of pediatric stroke care in the United States: a systematic and contemporary review. *Expert Rev Pharmacoecon Outcomes Res*. 2014 Jun 26:1-8.
165. Boan AD, Lackland DT, **Ovbiagele B**. Lowering of Blood Pressure for Recurrent Stroke Prevention. *Stroke*. 2014 2014 Aug;45(8):2506-13.
166. Owolabi MO, Akinyemi RO, Gebregziabher M, Olaniyan O, Salako BL, Arulogun O, **Ovbiagele B**. Randomized controlled trial of a multipronged intervention to improve blood pressure control among stroke survivors in Nigeria. *Int J Stroke*. 2014 Dec;9(8):1109-16.
167. Lee M, Saver JL, Hong KS, Wu YL, Liu HC, Rao NM, **Ovbiagele B**. Cognitive impairment and risk of future stroke: a systematic review and meta-analysis. *CMAJ*. 2014 Oct 7;186(14):E536-46.
168. **Ovbiagele B**, Schwamm LH, Smith EE, Grau-Sepulveda MV, Saver JL, Bhatt DL, Hernandez AF, Peterson ED, Fonarow GC. Hospitalized hemorrhagic stroke patients with renal insufficiency: clinical characteristics, care patterns, and outcomes. *J Stroke Cerebrovasc Dis*. 2014 Oct;23(9):2265-73.

169. Park JH, Lee J, **Ovbiagele B**. Nontraditional serum lipid variables and recurrent stroke risk. *Stroke*. 2014 Nov;45(11):3269-74.
170. **Ovbiagele B**, Smith EE, Schwamm LH, Grau-Sepulveda MV, Saver JL, Bhatt DL, Hernandez AF, Peterson ED, Fonarow GC. Chronic Kidney Disease and Bleeding Complications After Intravenous Thrombolytic Therapy for Acute Ischemic Stroke. *Circ Cardiovasc Qual Outcomes*. 2014 Sep 23. pii: CIRCOUTCOMES.114.001144. [Epub ahead of print]
171. **Ovbiagele B**, Kautz S, Feng W, Adkins DL. Poststroke outcomes. *Stroke Res Treat*. 2014;2014:828435.
172. Park JH, **Ovbiagele B**. Optimal combination secondary prevention drug treatment and stroke outcomes. *Neurology*. 2015 Jan 6;84(1):50-6.
173. **Ovbiagele B**. Phone-based intervention under nurse guidance after stroke: concept for lowering blood pressure after stroke in Sub-Saharan Africa. *J Stroke Cerebrovasc Dis*. 2015 Jan;24(1):1-9.
174. Lee M, Wu YL, Saver JL, Lee HC, Lee JD, Chang KC, Wu CY, Lee TH, Wang HH, Rao NM, **Ovbiagele B**. Is clopidogrel better than aspirin following breakthrough strokes while on aspirin? A retrospective cohort study. *BMJ Open*. 2014 Dec 2;4(12):e006672.
175. **Ovbiagele B**. Tackling the growing diabetes burden in Sub-Saharan Africa: a framework for enhancing outcomes in stroke patients. *J Neurol Sci*. 2015 Jan 15;348(1-2):136-41.
176. Park JH, **Ovbiagele B**. Stroke: LDL and stroke risk—clinical practice or target practice? *Nat Rev Neurol*. 2015 Jan;11(1):8-9.
177. Park JH, Kwon HM, **Ovbiagele B**. New Pooled Cohort Risk equations: application to a recent stroke patient population. *J Neurol Sci*. 2015 Jan 15;348(1-2):160-5.
178. Hsu CY, Wu YL, Cheng CY, Lee JD, Huang YC, Lee MH, Wu CY, Hsu HL, Lin YH, Huang YC, Yang HT, Yang JT, Lee M, **Ovbiagele B**. Low

Baseline Urine Creatinine Excretion Rate Predicts Poor Outcomes among Critically Ill Acute Stroke Patients. *Curr Neurovasc Res*. 2015;12(1):47-52.

179. Neil WP, Raman R, Hemmen TM, Ernststrom K, Meyer BC, Meyer DM, **Ovbiagele B**. Association of Hispanic ethnicity with acute ischemic stroke care processes and outcomes. *Ethn Dis*. 2015 Winter;25(1):19-23.
180. Lin MP, **Ovbiagele B**, Markovic D, Towfighi A. Systolic Blood Pressure and Mortality After Stroke: Too Low, No Go? *Stroke*. 2015 Mar 12. pii: STROKEAHA.115.008821. [Epub ahead of print]
181. Park JH, **Ovbiagele B**. Neurologic symptom severity after a recent noncardioembolic stroke and recurrent vascular risk. *J Stroke Cerebrovasc Dis*. 2015 May;24(5):1032-7.
182. Hurst S, Arulogun OS, Owolabi AO, Akinyemi R, Uvere E, Warth S, **Ovbiagele B**. Pretesting Qualitative Data Collection Procedures to Facilitate Methodological Adherence and Team Building in Nigeria. *Int J Qual Methods*. 2015;14:53-64.
183. Owolabi MO, Akarolo-Anthony S, Akinyemi R, Arnett D, Gebregziabher M, Jenkins C, Tiwari H, Arulogun O, Akpalu A, Sarfo FS, Obiako R, Owolabi L, Sagoe K, Melikam S, Adeoye AM, Lackland D, **Ovbiagele B**; as members of the H3Africa Consortium. The burden of stroke in Africa: a glance at the present and a glimpse into the future. *Cardiovasc J Afr*. 2015;26:S27-38.
184. Park JH, **Ovbiagele B**. Optimal combination treatment and vascular outcomes in recent ischemic stroke patients by premorbid risk level. *J Neurol Sci*. 2015.

B) Middle-authorship:

1. Leary MC, Kidwell CS, Villablanca JP, Starkman S, Jahan R, Duckwiler GR, Gobin YP, Sykes S, Gough KJ, Ferguson K, Llanes JN, Masamed R, Tremwel M, **Ovbiagele B**, Vespa PM, Vinuela F, Saver JL. Validation of computed tomographic middle cerebral artery "dot" sign: an angiographic correlation study. *Stroke*. 2003;34:2636-40.
2. Kidwell CS, Chalela JA, Saver JL, Starkman S, Hill MD, Demchuk AM, Butman JA, Patronas N, Alger JR, Latour LL, Luby ML, Baird AE, Leary MC, Tremwel M, **Ovbiagele B**, Fredieu A, Suzuki S, Villablanca JP, Davis S, Dunn B, Todd JW, Ezzeddine MA, Haymore J, Lynch JK, Davis L, Warach S.

Comparison of MRI and CT for detection of acute intracerebral hemorrhage. *JAMA*. 2004;292:1823-30.

3. Saver JL, Kidwell C, Eckstein M, **Ovbiagele B**, Starkman S. Physician-investigator phone elicitation of consent in the field: a novel method to obtain explicit informed consent for prehospital clinical research. *Prehosp Emerg Care*. 2006;10:182-5.
4. Marder VJ, Chute CJ, Starkman S, Abolian AM, Kidwell CK, Liebeskind DL, **Ovbiagele B**, Vinuela F, Duckwiler G, Jahan R, Vespa PM, Selco S, Rajajee V, Kim D, Sanossian N, Saver, JL. Analysis of Thrombi Retrieved from Cerebral Arteries of Patients with Acute Ischemic Stroke. *Stroke*. 2006;37:2086-93.
5. Rajajee V, Kidwell C, Starkman S, **Ovbiagele B**, Alger J, Villablanca P, Vinuela F, Duckwiler G, Jahan R, Fredieu A, Suzuki S, Saver JL. Early MRI and outcomes of untreated patients with mild or improving ischemic stroke. *Neurology*. 2006;67:980-4.
6. Kim D, Jahan R, Starkman S, Abolian A, Kidwell CS, Vinuela F, Duckwiler GR, **Ovbiagele B**, Vespa PM, Selco S, Venkatakrishna R, Saver JL. Endovascular mechanical clot retrieval in a broad ischemic stroke cohort. *AJNR Am J Neuroradiol*. 2006;27:2048-52.
7. Bang OY, Saver JL, **Ovbiagele B**, Choi YJ, Yoon SR, Lee KH. Adiponectin Levels in Patients with Intracranial Atherosclerosis. *Neurology*. 2007;68:1931-7.
8. Bang OY, Buck BH, Saver JL, Alger JR, Yoon SR, Starkman S, **Ovbiagele B**, Kim D, Ali LK, Sanossian N, Jahan R, Duckwiler GR, Vinuela F, Salamon N, Villablanca JP, Liebeskind DS. Prediction of hemorrhagic transformation after recanalization therapy using T2*-permeability magnetic resonance imaging. *Ann Neurol*. 2007 Aug 7; [Epub ahead of print]
9. Bang OY, Saver JL, Buck BH, Alger JR, Starkman S, **Ovbiagele B**, Kim D, Jahan R, Duckwiler GR, Yoon SR, Viñuela F, Liebeskind DS. Impact of collateral flow on tissue fate in acute ischemic stroke. *J Neurol Neurosurg Psychiatry*. 2007 Dec 20; [Epub ahead of print]
10. Rajajee V, Kidwell C, Starkman S, **Ovbiagele B**, Alger J, Villablanca P, Saver JL for the UCLA MRI Acute Stroke Investigators. Diagnosis of Lacunar Infarcts within 6 Hours of Onset by Clinical and CT Criteria Versus MRI. *J Neuroimaging*. 2008;18:66-72.
11. Nazliel B, Starkman S, Liebeskind DS, **Ovbiagele B**, Kim D, Sanossian N, Ali L, Buck B, Villablanca P, Vinuela F, Duckwiler G, Jahan R, Saver JL. A brief

prehospital stroke severity scale identifies ischemic stroke patients harboring persisting large arterial occlusions. Stroke. 2008;39(8):2264-7.

12. Sanossian N, Saver JL, Kim D, **Ovbiagele B**, Liebeskind DS. Angiography Reveals That FLAIR Vascular Hyperintensities Are Due To Slow Flow, Not Thrombus. AJNR 2009;30(3):564-8.
13. Bang OY, Liebeskind DS, Buck BH, Yoon SR, Alger JR, **Ovbiagele B**, Saver JL; for the UCLA MRI Investigators. Impact of Reperfusion after 3 Hours of Symptom Onset on Tissue Fate in Acute Cerebral Ischemia. J Neuroimaging. 2008 Oct 21
14. Bang OY, Saver JL, Alger JR, Starkman S, **Ovbiagele B**, Liebeskind DS; UCLA Collateral Investigators. Determinants of the distribution and severity of hypoperfusion in patients with ischemic stroke. Neurology. 2008;71(22):1804-11.
15. Bang OY, **Ovbiagele B**, Liebeskind DS, Restrepo L, Yoon SR, Saver JL. Clinical determinants of infarct pattern subtypes in large vessel atherosclerotic stroke. J Neurol. 2009;256(4):591-9.
16. Sanossian N, Saver JL, Alger JR, Kim D, Duckwiler GR, Jahan R, Vinuela F, **Ovbiagele B**, Liebeskind DS. Angiography reveals that fluid-attenuated inversion recovery vascular hyperintensities are due to slow flow, not thrombus. AJNR Am J Neuroradiol. 2009;30(3):564-8.
17. Bang OY, Saver JL, Alger JR, Shah SH, Buck BH, Starkman S, **Ovbiagele B**, Liebeskind DS; UCLA MRI Permeability Investigators. Patterns and predictors of blood-brain barrier permeability derangements in acute ischemic stroke. Stroke. 2009;40(2):454-61.
18. Restrepo L, Bang OY, **Ovbiagele B**, Ali L, Kim D, Liebeskind DS, Starkman S, Vinuela F, Duckwiler GR, Jahan R, Saver JL. Impact of hyperlipidemia and statins on ischemic stroke outcomes after intra-arterial fibrinolysis and percutaneous mechanical embolectomy. Cerebrovasc Dis. 2009;28(4):384-90.
19. Bang OY, Saver JL, Lee KH, Kim GM, Chung CS, Kim SJ, **Ovbiagele B**, Alger JR, Liebeskind DS; UCLA-Samsung Stroke Collaborators. Characteristics of patients with target magnetic resonance mismatch profile: data from two geographically and racially distinct populations. Cerebrovasc Dis. 2010;29(1):87-94.
20. Przeklasa-Auth M, **Ovbiagele B**, Yim C, Shewmon DA. Multiple Sclerosis With Initial Stroke-Like Clinicoradiologic Features: Case Report and Literature Review. J Child Neurol. 2009 Sep 30.

21. Gadhia J, Starkman S, **Ovbiagele B**, Ali L, Liebeskind D, Saver JL. Assessment and Improvement of Figures to Visually Convey Benefit and Risk of Stroke Thrombolysis. *Stroke*. 2010;41(2):300-6.
22. Kim JH, Bang OY, Liebeskind DS, **Ovbiagele B**, Kim GM, Chung CS, Lee KH, Saver JL; for the UCLA–Samsung Stroke Collaborators. Impact of Baseline Tissue Status (Diffusion-Weighted Imaging Lesion) Versus Perfusion Status (Severity of Hypoperfusion) on Hemorrhagic Transformation. *Stroke*. 2010;41(3):e135-e142.
23. Towfighi A, **Ovbiagele B**, Saver JL. Therapeutic milestone: stroke declines from the second to the third leading organ- and disease-specific cause of death in the United States. *Stroke*. 2010 Mar;41(3):499-503.
24. Smith EE, Pan W, Olson D, Reeves MJ, **Ovbiagele B**, Peterson ED, Fonarow GC, Schwamm LH. Frequency and determinants of lipid testing in ischemic stroke and transient ischemic attack: findings from get with the guidelines-stroke. *Stroke*. 2010;41(2):232-8
25. Bushnell CD, Zimmer LO, Pan W, Olson DM, Zhao X, Metelewa T, Schwamm L, **Ovbiagele B**, Williams L, LaBresh KA, Peterson ED. Persistence with Stroke Prevention Medications 3 Months after Hospitalization. *Arch Neurol*. 2010 Dec;67(12):1456-63
26. Shi ZS, Liebeskind DS, Loh Y, Saver JL, Starkman S, Vespa P, Gonzalez NR, Tateshima S, Jahan R, Miller C, Ali LK, **Ovbiagele B**, Kim D, Duckwiler GR, Vinuela F. Predictors of Subarachnoid Hemorrhage in Acute Ischemic Stroke with Endovascular Therapy. *Stroke* 2010. Dec;41(12):2775-81.
27. Bang OY, Saver JL, Kim SJ, Kim GM, Chung CS, **Ovbiagele B**, Lee KH, Liebeskind DS; UCLA-Samsung Stroke Collaborators. Collateral flow averts hemorrhagic transformation after endovascular therapy for acute ischemic stroke. *Stroke*. 2011 Aug;42(8):2235-9.
28. Bushnell CD, Olson DM, Zhao X, Pan W, Zimmer LO, Goldstein LB, Alberts MJ, Fagan SC, Fonarow GC, Johnston SC, Kidwell C, Labresh KA, **Ovbiagele B**, Schwamm L, Peterson ED; AVAIL Investigators. Secondary preventive medication persistence and adherence 1 year after stroke. *Neurology*. 2011 Sep 20;77(12):1182-90
29. Lee M, Saver JL, Alger JR, Hao Q, Starkman S, Ali LK, Kim D, **Ovbiagele B**, Vespa PM, Froehler MT, Tenser MS, Salamon N, Villablanca JP, Jahan R, Duckwiler GR, Tateshima S, Gonzalez N, Vinuela F, Liebeskind DS. Blood-brain barrier permeability derangements in posterior circulation ischemic

stroke: Frequency and relation to hemorrhagic transformation. *J Neurol Sci*. 2011 Sep 24.

30. Lee M, Saver JL, Alger JR, Hao Q, Salamon N, Starkman S, Ali LK, **Ovbiagele B**, Kim D, Villablanca JP, Froehler MT, Tenser MS, Liebeskind DS. Association of laterality and size of perfusion lesions on neurological deficit in acute supratentorial stroke. *Int J Stroke*. 2012 Jun;7(4):293-7.
31. Zhu L, Liebeskind DS, Jahan R, Starkman S, Salamon N, Duckwiler G, Vinuela F, Tateshima S, Gonzalez N, Villablanca P, Ali LK, Kim D, **Ovbiagele B**, Froehler M, Tenser M, Saver JL. Thrombus branching and vessel curvature are important determinants of middle cerebral artery trunk recanalization with Merci thrombectomy devices. *Stroke*. 2012 Mar;43(3):787-92.
32. Lee M, Saver JL, Hao Q, Starkman S, Salamon N, Ali LK, Kim D, **Ovbiagele B**, Song S, Raychev R, Abcede H, Fiaz R, Liebeskind DS; UCLA Stroke Investigators. Anterior choroidal artery ischaemic patterns predict outcome of carotid occlusion. *J Neurol Neurosurg Psychiatry*. 2012 Jun;83(6):586-90.
33. Shi ZS, Loh Y, Liebeskind DS, Saver JL, Gonzalez NR, Tateshima S, Jahan R, Feng L, Vespa PM, Starkman S, Salamon N, Villablanca JP, Ali LK, **Ovbiagele B**, Kim D, Viñuela F, Duckwiler GR. Leukoaraiosis predicts parenchymal hematoma after mechanical thrombectomy in acute ischemic stroke. *Stroke*. 2012 Jul;43(7):1806-11.
34. Yang HT, Lee M, Hong KS, **Ovbiagele B**, Saver JL. Efficacy of folic acid supplementation in cardiovascular disease prevention: an updated meta-analysis of randomized controlled trials. *Eur J Intern Med*. 2012 Dec;23(8):745-54.
35. Saposnik G, Guzik AK, Reeves M, **Ovbiagele B**, Johnston SC. Stroke Prognostication using Age and NIH Stroke Scale: SPAN-100. *Neurology*. 2013 Jan 1;80(1):21-8.
36. Yan T, Escarce JJ, Liang LJ, Longstreth WT Jr, Merkin SS, **Ovbiagele B**, Vassar SD, Seeman T, Sarkisian C, Brown AF. Exploring psychosocial pathways between neighbourhood characteristics and stroke in older adults: the cardiovascular health study. *Age Ageing*. 2013 May;42(3):391-7.
37. Brown AF, Liang LJ, Vassar SD, Merkin SS, Longstreth WT Jr, **Ovbiagele B**, Yan T, Escarce JJ. Neighborhood socioeconomic disadvantage and mortality after stroke. *Neurology*. 2013 Feb 5;80(6):520-7.

38. Saposnik G, Johnston SC, Raptis S, **Ovbiagele B**, Fisher M; on behalf of the Stroke Journal Editorial Board. Stroke Journal: What Is Being Published to Advance the Field? *Stroke*. 2013 Aug 1 [Epub ahead of print]
39. Bang OY, **Ovbiagele B**, Kim JS. Evaluation of Cryptogenic Stroke With Advanced Diagnostic Techniques. *Stroke*. 2014 Feb 27. [Epub ahead of print]
40. Lee MJ, Bang OY, Kim SJ, Kim GM, Chung CS, Lee KH, **Ovbiagele B**, Liebeskind DS, Saver JL. Role of Statin in Atrial Fibrillation-Related Stroke: An Angiographic Study for Collateral Flow. *Cerebrovasc Dis*. 2014 Jan 16;37(2):77-84.
41. Owolabi MO, Mensah GA, Kimmel PL, Adu D, Ramsay M, Waddy SP, **Ovbiagele B**, Rabada-Diehl C, Rasooly R, Akarolo-Anthony SN, Rotimi C; H3Africa Consortium. Understanding the rise in cardiovascular diseases in Africa: harmonising H3Africa genomic epidemiological teams and tools. *Cardiovasc J Afr*. 2014 May/June 24;25(3):134-136.
42. Saposnik G, **Ovbiagele B**, Raptis S, Fisher M, Johnston SC. Effect of english proficiency and research funding on acceptance of submitted articles to stroke journal. *Stroke*. 2014 Jun;45(6):1862-8.
43. Boan AD, Feng WW, **Ovbiagele B**, Bachman DL, Ellis C, Adams RJ, Kautz SA, Lackland DT. Persistent racial disparity in stroke hospitalization and economic impact in young adults in the buckle of stroke belt. *Stroke*. 2014 Jul;45(7):1932-8.
44. Sposato LA, **Ovbiagele B**, Johnston SC, Fisher M, Saposnik G; Stroke Outcome Research Working Group (www.sorcan.ca). A peek behind the curtain: peer review and editorial decision making at Stroke. *Ann Neurol*. 2014 Aug;76(2):151-8.
45. Boan AD, Voeks JH, Feng WW, Bachman DL, Jauch EC, Adams RJ, **Ovbiagele B**, Lackland DT. The Impact of ICD-9 Revascularization Procedure Codes on Estimates of Racial Disparities in Ischemic Stroke. *J Stroke Cerebrovasc Dis*. 2014 Sep 25. pii: S1052-3057(14)00290-0. doi: 10.1016/j.jstrokecerebrovasdis.2014.06.008. [Epub ahead of print]

46. Ellis C, Hyacinth HI, Beckett J, Feng W, Chimowitz M, **Ovbiagele B**, Lackland D, Adams R. Racial/Ethnic differences in poststroke rehabilitation outcomes. *Stroke Res Treat*. 2014;2014:950746.
47. Boan AD, Egan BM, Bachman DL, Adams RJ, Feng WW, Jauch EC, **Ovbiagele B**, Lackland DT. Antihypertensive Medication Persistence 1-Year Post-Stroke Hospitalization. *J Clin Hypertens (Greenwich)*. 2014 Oct 13. doi: 10.1111/jch.12424. [Epub ahead of print]
48. Park JH, Park JH, **Ovbiagele B**, Kwon HM, Lim JS, Kim JY, Cho B, Yun JM, Lee H. New Pooled Cohort Risk Equations and Presence of Asymptomatic Brain Infarction. *Stroke*. 2014 Oct 28. pii: STROKEAHA.114.006971. [Epub ahead of print]
49. Krishnan P, Saposnik G, **Ovbiagele B**, Zhang L, Symons S, Aviv R. Contribution and Additional Impact of Imaging to the SPAN-100 Score. *Am J Neuroradiol*. 2015 Apr;36(4):646-52.
50. Arshi B, **Ovbiagele B**, Markovic D, Saposnik G, Towfighi A. Differential effect of B-vitamin therapy by antiplatelet use on risk of recurrent vascular events after stroke. *Stroke*. 2015 Mar;46(3):870-3.
51. Park JH, **Ovbiagele B**, Feng W. Stroke and sexual dysfunction - a narrative review. *J Neurol Sci*. 2015 Mar 15;350(1-2):7-13.
52. Lin MP, **Ovbiagele B**, Markovic D, Towfighi A. Systolic blood pressure and mortality after stroke: too low, no go? *Stroke*. 2015 May;46(5):1307-13.
53. Akinyemi RO, **Ovbiagele B**, Akpalu A, Jenkins C, Sagoe K, Owolabi L, Sarfo F, Obiako R, Gebreziabher M, Melikam E, Warth S, Arulogun O, Lackland D, Ogunniyi A, Tiwari H, Kalaria RN, Arnett D, Owolabi MO; SIREN investigators as members of the H3Africa Consortium. Stroke genomics in people of African ancestry: charting new paths. *Cardiovasc J Afr*. 2015;26:S39-49.
54. Lee M, **Ovbiagele B**, Hong KS, Wu YL, Lee JE, Rao NM, Feng W, Saver JL. Effect of Blood Pressure Lowering in Early Ischemic Stroke: Meta-Analysis. *Stroke*. 2015 May 28.

55. McManus M, **Ovbiagele B**, Markovic D, Towfighi A. Association of Insurance Status with Stroke-Related Mortality and Long-term Survival after Stroke. J Stroke Cerebrovasc Dis. 2015 Jun 4.

C) Group Authorship (Collaborative studies):

1. Toole JF, et al. VISP Trial Investigators. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA. 2004;291:565-75.
2. Muir KW, et al. Intravenous Magnesium Efficacy in Stroke (IMAGES) Study Investigators. Magnesium for acute stroke (Intravenous Magnesium Efficacy in Stroke trial): randomised controlled trial. Lancet. 2004;363:439-45.
3. Saver JL, et al; FAST-MAG Pilot Trial Investigators. Pre-hospital neuroprotective therapy for acute stroke: results of the Field Administration of Stroke Therapy-Magnesium (FAST-MAG) pilot trial. Stroke. 2004;35:e106-8.
4. California Acute Stroke Pilot Registry (CASPR) Investigators. Prioritizing interventions to improve rates of thrombolysis for ischemic stroke. Neurology. 2005;64:654-9.
5. Chimowitz MI, et al; Warfarin-Aspirin Symptomatic Intracranial Disease Trial Investigators. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med. 2005;352:1305-16.
6. Smith WS, et al; MERCI Trial Investigators. Safety and efficacy of mechanical embolectomy in acute ischemic stroke: results of the MERCI trial. Stroke. 2005;36:1432-8.
7. California Acute Stroke Pilot Registry (CASPR) Investigators. The impact of standardized stroke orders on adherence to best practices. Neurology. 2005;65:360-5.
8. Chen DT, et al. SWISS Investigators. The impact of privacy protections on recruitment in a multicenter stroke genetics study. Neurology 2005;64:721-724.
9. Worrall BB, et al. SWISS Investigators. A survey of the SWISS researchers on the impact of sibling privacy protections on pedigree recruitment. Neuroepidemiology 2005;25:32-41.
10. Meschia JF, et al. SWISS Investigators. Correlation of proband and sibling stroke latency: the SWISS study. Neurology 2005;64:1061-1063.
11. Meschia JF, et al. SWISS Investigators. Phosphodiesterase 4D and 5-lipoxygenase activating protein in ischemic stroke. Annals of Neurology 2005;58:351-61.
12. Smith WS, et al. Multi MERCI Investigators. Safety of Mechanical Thrombectomy and Intravenous Tissue Plasminogen Activator in Acute Ischemic Stroke. Results of the Multi Mechanical Embolus Removal in Cerebral Ischemia (MERCI) Trial, Part I. AJNR Am J Neuroradiol. 2006;27:1177-82.

13. Neumann-Haefelin T, et al. MR Stroke Group. Leukoaraiosis Is a Risk Factor for Symptomatic Intracerebral Hemorrhage After Thrombolysis for Acute Stroke. *Stroke* 2006;37:2463-6.
14. Kim D et al; UCLA Intra-Arterial Thrombolysis Investigators. Intra-Arterial Thrombolysis for Acute Stroke in Patients 80 and Older: A Comparison of Results in Patients Less than 80. *AJNR Am J Neuroradiol*. 2007;28:159-63.
15. Smith WS, Sung G, Saver J, Budzik R, Duckwiler G, Liebeskind DS, Lutsep HL, Rymer MM, Higashida RT, Starkman S, Gobin YP; Multi MERCI Investigators, et al. Mechanical thrombectomy for acute ischemic stroke: final results of the Multi MERCI trial. *Stroke*. 2008;39:1205-12.
16. Smith WS, Sung G, Saver J, Budzik R, Duckwiler G, Liebeskind DS, Lutsep HL, Rymer MM, Higashida RT, Starkman S, Gobin YP; Multi MERCI Investigators, et al. Mechanical thrombectomy for acute ischemic stroke: final results of the Multi MERCI trial. *Stroke*. 2008;39:1205-12.
17. Yusuf S et al, PROFESS Study Group. Telmisartan to prevent recurrent stroke and cardiovascular events. *N Engl J Med*. 2008;359:1225-37.
18. Sacco RL et al, PROFESS Study Group. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. *N Engl J Med*. 2008;359:1238-51.
19. Diener HC et al, PROFESS Study Group. Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PROFESS) trial: a double-blind, active and placebo-controlled study. *Lancet Neurol*. 2008;7(10):875-84.
20. Pancioli AM, Broderick J, Brott T, Tomsick T, Khoury J, Bean J, del Zoppo G, Kleindorfer D, Woo D, Khatri P, Castaldo J, Frey J, Gebel J Jr, Kasner S, Kidwell C, Kwiatkowski T, Libman R, Mackenzie R, Scott P, Starkman S, Thurman RJ; CLEAR Trial Investigators. The combined approach to lysis utilizing eptifibatide and rt-PA in acute ischemic stroke: the CLEAR stroke trial. *Stroke*. 2008;39(12):3268-76.
21. Hallevi H, Barreto AD, Liebeskind DS, Morales MM, Martin-Schild SB, Abraham AT, Gadia J, Saver JL; UCLA Intra-Arterial Therapy Investigators, Grotta JC, Savitz SI. Identifying patients at high risk for poor outcome after intra-arterial therapy for acute ischemic stroke. *Stroke*. 2009 May;40(5):1780-5.
22. Singer OC, Berkefeld J, Lorenz MW, Fiehler J, Albers GW, Lansberg MG, Kastrup A, Rovira A, Liebeskind DS, Gass A, Rosso C, Derex L, Kim JS, Neumann-Haefelin T; MR Stroke Study Group Investigators. Risk of symptomatic intracerebral hemorrhage in patients treated with intra-arterial thrombolysis. *Cerebrovasc Dis*. 2009;27(4):368-74.
23. Kernan WN, Viscoli CM, Demarco D, Mendes B, Shrauger K, Schindler JL, McVeety JC, Sicklick A, Moalli D, Greco P, Bravata DM, Eisen S, Resor L, Sena K, Story D, Brass LM, Furie KL, Gutmann L, Hinnau E, Gorman M, Lovejoy AM, Inzucchi SE, Young LH, Horwitz RI; IRIS Trial Investigators. Boosting enrollment in neurology trials with Local Identification

- and Outreach Networks (LIONS). *Neurology*. 2009 Apr 14;72(15):1345-51.
24. Singer OC, Kurre W, Humpich MC, Lorenz MW, Kastrup A, Liebeskind DS, Thomalla G, Fiehler J, Berkefeld J, Neumann-Haefelin T; MR Stroke Study Group Investigators. Risk assessment of symptomatic intracerebral hemorrhage after thrombolysis using DWI-ASPECTS. *Stroke*. 2009 Aug;40(8):2743-8.
 25. Shi ZS, Loh Y, Walker G, Duckwiler GR; MERCI and Multi-MERCI Investigators. Clinical outcomes in middle cerebral artery trunk occlusions versus secondary division occlusions after mechanical thrombectomy: pooled analysis of the Mechanical Embolus Removal in Cerebral Ischemia (MERCI) and Multi MERCI trials. *Stroke*. 2010 May;41(5):953-60.
 26. Powers WJ, Clarke WR, Grubb RL Jr, Videen TO, Adams HP Jr, Derdeyn CP; COSS Investigators. Extracranial-intracranial bypass surgery for stroke prevention in hemodynamic cerebral ischemia: the Carotid Occlusion Surgery Study randomized trial. *JAMA*. 2011 Nov 9;306(18):1983-92.
 27. Ali M, Hazelton C, Lyden P, Pollock A, Brady M; VISTA Collaboration. Recovery from poststroke visual impairment: evidence from a clinical trials resource. *Neurorehabil Neural Repair*. 2013 Feb;27(2):133-41.
 28. Kidwell CS, Jahan R, Gornbein J, Alger JR, Nenov V, Ajani Z, Feng L, Meyer BC, Olson S, Schwamm LH, Yoo AJ, Marshall RS, Meyers PM, Yavagal DR, Wintermark M, Guzy J, Starkman S, Saver JL; MR RESCUE Investigators. A trial of imaging selection and endovascular treatment for ischemic stroke. *N Engl J Med*. 2013 Mar 7;368(10):914-23.
 29. Carroll JD, Saver JL, Thaler DE, Smalling RW, Berry S, MacDonald LA, Marks DS, Tirschwell DL; RESPECT Investigators. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. *N Engl J Med*. 2013 Mar 21;368(12):1092-100.
 30. Ali M, Fulton R, Quinn T, Brady M; VISTA Collaboration. How well do standard stroke outcome measures reflect quality of life? A retrospective analysis of clinical trial data. *Stroke*. 2013 Nov;44(11):3161-5.
 31. Saposnik G, Chow CM, Gladstone D, Cheung D, Brawer E, Thorpe KE, Saldanha A, Dang A, Bayley M, Schweizer TA; iHOME Research Team for the Stroke Outcomes Research Canada Working Group. iPad technology for home rehabilitation after stroke (iHOME): a proof-of-concept randomized trial. *Int J Stroke*. 2014 Oct;9(7):956-62.
 32. Saver JL, Starkman S, Eckstein M, Stratton SJ, Pratt FD, Hamilton S, Conwit R, Liebeskind DS, Sung G, Kramer I, Moreau G, Goldweber R, Sanossian N; FAST-MAG Investigators and Coordinators. Prehospital use of magnesium sulfate as neuroprotection in acute stroke. *N Engl J Med*. 2015 Feb 5;372(6):528-36.

D) Scientific and Policy Guideline Statements

1. Furie K, Kasner SE, Adams RJ, Albers GW, Bush RL, Fagan S, Johnston SC, Katzan I, Kernan WN, Mitchell P, **Ovbiagele B**, Palesch Y, Sacco RL, Schwamm LH, Wassertheil-Smoller S, Halperin J, Turan T, Wentworth D.

Guidelines for the Prevention of Stroke in Patients with Stroke and Transient Ischemic Attack. A Statement for Healthcare Professionals from the American Heart Association/American Stroke Association Council on Stroke Co-Sponsored by Cardiovascular Nursing Council; Clinical Cardiology Council; and Quality of Care and Outcomes Research Interdisciplinary Working Group. The American Academy of Neurology (AAN) affirms the value of this guideline as an educational tool for neurologists. *Stroke*. 2011 Jan;42(1):227-76.

2. Cruz-Flores S, Rabinstein A, Biller J, Elkind MS, Griffith P, Gorelick PB, Howard G, Leira EC, Morgenstern LB, **Ovbiagele B**, Peterson E, Rosamond W, Trimble B, Valderrama AL; on behalf of the American Heart Association Stroke Council; Council on Cardiovascular Nursing; Council on Epidemiology and Prevention, and Council on Quality of Care and Outcomes Research. Racial-Ethnic Disparities in Stroke Care: The American Experience: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association. *Stroke*. 2011 Jul;42(7):2091-2116.
3. **Ovbiagele B**, Goldstein LB, Higashida RT, Howard VJ, Johnston SC, Khavjou OA, Lackland DT, Lichtman JH, Mohl S, Sacco RL, Saver JL, Trogon JG; American Heart Association Advocacy Coordinating Committee and Stroke Council. Forecasting the future of stroke in the United States: a policy statement from the American Heart Association and American Stroke Association. *Stroke*. 2013 Aug;44(8):2361-75.
4. Kernan WN, **Ovbiagele B**, Black HR, Bravata DM, Chimowitz MI, Ezekowitz MD, Fang MC, Fisher M, Furie KL, Heck DV, Johnston SC, Kasner SE, Kittner SJ, Mitchell PH, Rich MW, Richardson D, Schwamm LH, Wilson JA; on behalf of the American Heart Association Stroke Council, Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology, and Council on Peripheral Vascular Disease. Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. *Stroke*. 2014 May 1. [Epub ahead of print]
5. Powers WJ, Derdeyn CP, Biller J, Coffey CS, Hoh BL, Jauch EC, Johnston KC, Johnston SC, Khalessi AA, Kidwell CS, Meschia JF, **Ovbiagele B**, Yavagal DR; American Heart Association Stroke Council. 2015 AHA/ASA Focused Update of the 2013 Guidelines for the Early Management of Patients With Acute Ischemic Stroke Regarding Endovascular Treatment: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. *Stroke*. 2015 Jun 29.

EDITORIAL LETTERS (Peer Review Journals)

1. **Ovbiagele B**. High-dose statins in acute coronary syndromes. *JAMA*. 2005;293:36-7
2. **Ovbiagele B**, Saver JL. Comments on 'when to measure lipid profile after stroke'. *Cerebrovasc Dis*. 2005;20:211.

3. **Ovbiagele B.** HMG-CoA Reductase Inhibitors Improve Acute Ischemic Stroke Clinical Outcomes. *Stroke*. 2005;36:2344
4. **Ovbiagele B.** Association of the metabolic syndrome with intracranial atherosclerotic stroke. *Neurology*. 2006;66:459
5. **Ovbiagele B,** Saver JL. The smoking-thrombolysis paradox and acute ischemic stroke; reply from the authors: *Neurology*. 2006;66:458
6. **Ovbiagele B.** Cholesterol and risk of stroke: Study lumps apples and oranges. *BMJ* 2006;333:148
7. Sanossian N, **Ovbiagele B.** Premorbid antiplatelet use and ischemic stroke outcomes; reply from the authors: *Neurology*. 2006; 2006;67:1723.
8. Sanossian N, Saver JL, **Ovbiagele B.** Aspirin and Stroke Severity. *Stroke* 2006;37:2660.
9. **Ovbiagele B.** Composite Approach to Solving the Composite Trial Endpoint Problem. *BMJ Online* 2007.
10. Saposnik G, Johnston SC, **Ovbiagele B;** VISTA Collaboration. "Predicting clinical outcomes after thrombolysis using the iScore: results from the Virtual International Stroke Trials Archive". *Stroke*. 2013 Nov;44(11):e155.
11. **Ovbiagele B,** Kidwell CS. "Association of chronic kidney disease with cerebral microbleeds in patients with primary intracerebral hemorrhage". *Stroke*. 2013 Dec;44(12):e232.
12. Feng WW, **Ovbiagele B.** Could immediate blood pressure reduction after acute ischemic stroke prevent early recurrent strokes? *J Neurol Sci*. 2014
13. Owolabi MO, **Ovbiagele B.** Global clinical neuroscience: Journey of a thousand miles begins with a single step. *J Neurol Sci*. 2014 Jun 17. pii: S0022-510X(14)00381-5.
14. **Ovbiagele B,** Saposnik G. Risk index and thrombolytic treatment in acute ischemic stroke-reply. *JAMA Neurol*. 2014 Oct 1;71(10):1326.
15. Kernan WN, **Ovbiagele B,** Kittner SJ. Response to letter regarding article, "guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the american heart association/american stroke association". *Stroke*. 2015 Apr;46(4):e87-9.

COMMENTARIES

1. Selco SL, **Ovbiagele B.** *Intravenous Magnesium administered within 12 hours of Ischemic Stroke Onset Does not Reduce Death and Disability at 90 Days – Commentary on the IMAGES trial.* Evidence-based Healthcare 2004;8: 227-229
2. **Ovbiagele B.** *PROTECT: A secondary prevention success story that bears repeating.* Expert Commentaries for Atherothrombosis.org. December 2004.
3. **Ovbiagele B.** *Adherence to ATP guidelines for post-stroke statin use, poor but improving.* Expert Commentaries for Atherothrombosis.org. June 2006.
4. **Ovbiagele B.** *High-dose atorvastatin after stroke or transient ischemic attack.* Nature Clin Pract Neurol. 2007;3:130-1.
5. **Ovbiagele B.** *Unified Score Enhances Early Stroke Prediction After TIA.* Journal Watch Neurology March 27, 2007.
6. Sanossian N, **Ovbiagele B.** *Interrupting Statins Worsens Acute Stroke Outcomes.* Journal Watch Neurology. December 11, 2007.
7. Shah SH, **Ovbiagele B.** *Brain CT Findings Enhance Prediction of Stroke after TIA* Journal Watch Neurology. April 29, 2008.
8. Teng E, **Ovbiagele B.** *Statin Use and Incident Cognitive Impairment or Dementia* Journal Watch Neurology. November 4, 2008.
9. Abcede H, **Ovbiagele B.** *Prompt TIA and Minor Stroke Management.* Journal Watch Neurology. May 26, 2009.
10. **Ovbiagele B.** *Cilostazol vs. Aspirin for Recurrent-Stroke Prevention.* Journal Watch Neurology. October 26, 2010
11. **Ovbiagele B.** *Dabigatran Is Approved for Atrial Fibrillation.* Journal Watch Neurology. November 9, 2010
12. **Ovbiagele B.** *Brain and Vascular Imaging Improve Prediction of Early Stroke After TIA.* Journal Watch Neurology. December 7, 2010
13. **Ovbiagele B.** *Endarterectomy vs. Carotid Stenting: A Meta-Analysis.* Journal Watch Neurology. February 8, 2011

14. **Ovbiagele B.** *Blood Pressure Reduction in Acute Stroke.* Journal Watch Neurology. March 1, 2011
15. **Ovbiagele B.** *Stroke Center Designation and Mortality.* Journal Watch Neurology. March 1, 2011
16. **Ovbiagele B.** *Updated Guidelines on Secondary Stroke Prevention.* Journal Watch Neurology. March 8, 2011
17. **Ovbiagele B.** *Aspirin Discontinuation and Cerebrovascular Events.* Journal Watch Neurology. April 5, 2011
18. **Ovbiagele B.** *SAMMPRIS Trial Halted.* Journal Watch Neurology. May 3, 2011
19. Meyer BJ, **Ovbiagele B.** *Guidelines: Extracranial Carotid and Vertebral Artery Disease.* Journal Watch Neurology May 10, 2011
20. **Ovbiagele B.** *Alteplase Dose for Ischemic Stroke in Very Heavy Patients.* Journal Watch Neurology June 21, 2011
21. **Ovbiagele B.** *Carotid Endarterectomy: Too Soon to Call It Preferred for Women.* Journal Watch Neurology June 28, 2011
22. **Ovbiagele B.** *Depression After Transient Ischemic Attack.* Journal Watch Neurology August 16, 2011
23. **Ovbiagele B.** *Ultrasound Measurements May Stratify Stroke Risk with Asymptomatic Carotid Stenosis.* Journal Watch Neurology August 30, 2011
24. Brett AS, **Ovbiagele B.** *Body-Weight–Supported Treadmill Rehabilitation After Stroke.* Journal Watch Neurology September 20, 2011
25. **Ovbiagele B.** *Intensive Medical Therapy vs. Stenting for Severe Symptomatic Intracranial Stenosis.* Journal Watch Neurology September 20, 2011
26. **Ovbiagele B.** *Intracranial Hemorrhage After Revascularization.* Journal Watch Neurology October 4, 2011
27. **Ovbiagele B.** *Depression as a Stroke Risk Factor.* Journal Watch Neurology November 7, 2011

28. **Ovbiagele B**. *What's New in Vascular Neurology*. Med Princ Pract. 2012 May 8.

BOOKS

1. **Ovbiagele B** (Editor). *Stroke Management and Recovery*. FUTURE SCIENCE GROUP. London, United Kingdom. Published in May 2013
2. **Ovbiagele B** (Editor). *Best Practices in Neurological Care*. February, 2014. Copyright © 2014 Future Medicine Ltd, London, United Kingdom. doi: 10.2217/9781780842790.
3. **Ovbiagele B** and Turan T (Editors). *Ischemic Stroke Therapeutics: A Comprehensive Guide*. Copyright © 2015 Springer Science. New York City, New York.

BOOK CHAPTERS

1. Kidwell CS, Saver JL, **Ovbiagele B**, Warach S. Brain Imaging in Stroke. *Handbook of Cerebrovascular Diseases*. Adams HP Jr.(ed). Chapter 5. MARCEL DEKKER INC, New York 2005.
2. Shah SH, **Ovbiagele B**. *Transient Ischemic Attacks*. *International Neurology*. Lisak R, Truong D, Carroll, and Bhidayasiri R (eds). First edition. Blackwell Publishing Ltd. 2009
3. Yamada L, Ozark S, **Ovbiagele B**. *Transient Ischemic Attacks*. *International Neurology*. Lisak R, Truong D, Carroll, and Bhidayasiri R (eds). Second Edition. Blackwell Publishing Limited. 2014
4. Khouri G, Ozark S, **Ovbiagele B**. *Common Risk factors for Stroke and Medical Prevention Therapies*. *Neurobiology of Disease*. Second Edition. Johnston M (ed). Oxford University Press, New York City, New York. 2014

ABSTRACTS

- Authorship/co-authorship on 351 peer-reviewed abstracts (2002 to date) presented at national and international meetings (can be furnished on request)